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Hearing impairment occurs when a child has hearing loss greater than 30dB in their better 
hearing ear and an adult cannot detect sound lower than 40dB in the better hearing ear. It is a 
common sensory disorder that affecting approximately 360 million worldwide, with an 
incidence of 6 in 1000 live births in developing countries such as those in Sub-Saharan Africa. 
50 % of hearing impairment, in developed countries, is due to genetic factors, with 70% of 
genetic hearing impairment being classified as non-syndromic hearing impairment, which 
occurs when the hearing impairment presents with no other clinical manifestations. Hearing 
impairment is associated with over 150 genes, of which two connexin genes, GJB2 and GJB6, 
are the most prevalent genes associated with hearing impairment in European, Asian and North 
American of European ancestries populations. These genes have however been shown to be 
insignificant causes of Hearing Impairment in African populations 
 
Aim  
The aim of this study is to determine the rates for putative pathogenic variants in 172 hearing 
impairment associated genes, among Cameroonian patients affected by hearing impairment, 
and non-hearing-impaired controls. 
 
Methods 
Patients and controls 
Patients were recruited from various schools of the Deaf and Ear, Nose and Throat (ENT) 
clinics in Cameroon. The patients were examined by qualified medical geneticists and 
ophthalmologist and detailed family history and medical history was obtained from the patients 
and their parents. 19 patients, who were negative for GJB2 and GJB6 mutations and presented 
with putative non-syndromic hearing impairment, were selected from a cohort of 582 patients 
for the present study.  
The control population consisted of 130 ethnically matched groups without any personal or 
familial history of hearing impairment. The controls were recruited from Yaoundé Central 




Whole exome sequencing  
DNA was extracted from whole blood using the salting out procedure and the Puregene Blood 
kit®. The DNA was subjected to spectrometry and gel electrophoresis to determine the quantity 
and quality of the DNA samples. The samples were then subjected to whole exome sequencing 
on the Illumina platform using the Nextera Rapid Capture Exome Kit at an average read depth 
of 30X, whereby only 18 patients were successfully sequenced. The exomes were then 
subjected to FastQC and SolexaQC++ for quality control measures and aligned to the hg19 
reference genome using GATK and VariantMetaCaller.  
 
Bioinformatics analysis 
Variant annotation was performed using Annovar and the annotated variants were filtered 
based in rarity and pathogenicity. Tests for genetic differentiation and principle component 
analysis was performed on the combined patient exomes and combine control exomes. The 
first principle component analysis included data from African populations from the 1000 
Genomes Phase 3 as well as six control samples from the Democratic Republic of Congo; and 
the second principle component analysis analysed on the Cameroonian patients and control 
population. Population structure analysis was followed by protein-protein interaction analysis 
using custom python and R script and pathway enrichment analysis using Enrichr combined 
with a second custom R script.  
The proportion of derived and ancestral alleles was computed by downloading the SNP 
ancestral alleles from Ensembl and verifying the presence of the SNPs in dbSNP database. The 
combined patient and control exomes were annotated using the VCFtools “fillOaa” script. The 
ancestral alleles were computed by dividing the number of times the alternative allele matched 
the ancestral allele with the number of copies of all the alternative alleles across all samples at 
the particular position. The ancestral alleles were categorised into six bins, based on their minor 
allele frequency, in the patient and control populations and this was used to contrast their 
proportions of derived and ancestral alleles. Furthermore, the proportion of ancestral and 
derived alleles in hearing impairment associated genes was computed at SNP based level for 
the Cameroonian population and contrasted with population from the Democratic Republic of 
Congo. 
 
Variants validation by Sanger sequencing 
Primers were designed to amplify the fragment surrounding the purported SNPs in MYO15A, 
MYO3A, and COL9A3 as well as for the fragments surrounding the population specific SNPs 
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in VTN, RPL3L and DHRS4L2. Polymerase chain reaction was performed for the MYO15A, 
and MYO3A fragments. This was followed by purification of the PCR products and direct cycle 
Sanger sequencing of the PCR products. The sequencing products were then purified through 
ethanol precipitation and the fragments were suspended in HiDi Formamide and run on the 
capillary electrophoresis. The variants in MYO3A, MYO15A and COL9A3 were viewed in 
Integrated Genomics Viewer using the Bam files as well. 
 
Results 
Putative deleterious variants 
Single nucleotide polymorphism (SNPs) in MYO3A, MYO15A and COL9A3, were filtered out 
as putative causative mutations for three, four and two patients respectively. Direct Sanger 
Sequencing and viewing the patients BAM files did not confirm the presence of any of these 
putative pathogenic in the patients. Variations in USH2A, HSD17B4 and MYO1A were also 
filtered out but these variants were not considered disease causing, after a careful genotype to 
phenotypes correlations.  
 
Population genetics variants differentiations 
At a population level, specific variations were identified in FOXD4L2, DHRS2L6, RPL3L and 
VTN. Significant genetic differentiation was shown to exist between the control population and 
the patients’ population with regard to specific variants in VTN and RPL3L; furthermore, it was 
shown that these variants in VTN and RPL3L interact with other hearing impairment associated 
proteins with evidences that that VTN is hub protein for a hearing impairment associated 
pathway along with nine other genes. Conversely, this was not the case for variants described 
in FOXD4L2 and DHRS2L6. 
In known hearing Impairment genes, the proportion of ancestral alleles was lowest for the 
patients’ population for variations with minor allele frequencies between 0.0 and 0.1. The 
proportion of derived and ancestral alleles was also shown to differ between the Cameroonian 
and the population from the Democratic Republic of Congo, indication possible regional 
differences in aetiology of Hearing impairment amongst multiple African populations.  
 
Discussion 
Low putative pathogenic variants in known hearing impairment genes among Africans  
The low pick up rate for putative pathogenic variants in our patients follows a similar trend 
observed in the African American populations, with hearing impairment, as well as data from 
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targeted exome sequencing from South African and Nigerian populations. This result is also in 
agreeance with other studies that interrogated hearing impairment in African populations 
utilising other means besides next generation sequencing. This result also highlights the 
importance of validating any results obtained from next generation sequencing through 
traditional approaches such as Sanger Sequencing or viewing the BAM files on IGV, 
specifically in African population, poorly represented in Exome databases. 
 
Bioinformatics Analysis Exhibited some Specific Variants among Cameroonian 
Protein-protein interactions and enrichment analysis indicated that VTN and RPL3L, and their 
interacting proteins, are significantly associated with osteoclast differentiation, which is 
associated with hearing impairment in osteogenesis imperfecta. VTN was further shown as a 
hub protein of a protein subnetwork, along ATPB2. The presence of a second protein acting as 
a hub protein may account for why aberrations in VTN have not been associated with a disease; 
whereby ATPB2 may ameliorate the pathogenic phenotype that ought to be observed in the 
presence of null mutations in VTN. 
 
Evolutionary adaptation of human hearing 
Data indicates the patient population carried a higher proportion of derived alleles in known 
hearing impairment genes, at low minor allele frequencies; possibly indicating, the interactive 
modifiers capacities of multiple hearing impairment genes, or alternatively, the polygenetic 
nature of hearing impairment in some patients. The proportion of ancestral and derived alleles 
was contrasted in the Cameroonian and the population from the Democratic Republic of Congo 
and it indicated that the variations that may result in hearing impairment in the one population 
may not be the same variations that result in hearing impairment in the other population Due 
to this, it is necessary to determine the causative variants resulting in disease in each of these 
populations independently.  
 
Conclusion and perspectives 
The results support a low pick up rate of putative variants in 172 known genes in groups of 
Cameroonian patients with HI, underscoring the current Targeted panel sequencing for HI may 
not be relevant for some African populations. The result also support the need of confirmation 
of variants found in WES, as well careful genotype to phenotypes correlations, particularly 
among African, whose sequences exome is relatively low in Exomes databases, and as a result 
could lead to more false positive results.  Population genetic analysis has provided novel insight 
5 
 
in the genetic architecture of HI among this group of Africans; particularly, the differential 
frequencies of ancestral alleles vs derived alleles in HI genes among patients vs controls 
underline the possibility of multigenic influence on the phenotype of Hearing Impairment that 
have not been well investigated, and may also signal evolutionary enrichment of some variants 
of HI genes in the populations as the result of natural selections, that deserve further 
investigation. The result supports the need of intensive familial studies in multiple African 
populations in order to unravel the novel genes and those variants that are relevant in clinical 




Chapter 1: Introduction and literature review 
Chapter 1.1: Overview 
The review by Wilson and colleagues, published in The Lancet, highlights the increasing 
burden of hearing impairment (HI) and provides recommendations to limit it (Wilson et al., 
2017). HI has progressed from the 11th leading cause of disability globally in 2010 to the fourth 
in 2013 (Murray et al., 2015). More than 80% of people affected by HI live in low and middle-
income countries, specifically in sub-Saharan Africa (SSA) with up to 6 per 1000 newborn 
affected per year (Olusanya et al., 2014). Major efforts are needed to reduce the burden of HI 
in SSA which is already ill-prepared to cope with more visible conditions such as HIV, malaria, 
cardiovascular diseases, and cancers. HI is a common sensory impairment affecting 
approximately 360 million people worldwide with the highest incidence of HI in developing 
countries. HI is considered disabling HI when a child cannot hear better than 30dB and an adult 
cannot hear better than 40dB (WHO Media Centre, 2017) 
Hearing impairment may arise from genetic, environmental and unknown factors with the 
majority (50%) of HI cases, in developed countries, being the result of genetic factors 
(Schrijver, 2004). In developing countries, the environment contributes the majority of HI, but 
genetics investigations even of familial cases have been lacking and genetic causes 
underestimated (Wonkam et al., 2013) 
Non-syndromic HI accounts for approximately 70% of genetic HI (Schrijver, 2004) and it 
describes the condition where the HI occurs without any additional clinical manifestations. Of 
the proportion of non-syndromic HI, 70 to 80% is due to autosomal recessive inheritance 
(Chung et al., 1959; Morton, 1991). Autosomal dominant inheritance accounts for 15 to 25 
percent and sex-linked and mitochondrial inheritance accounts for the remaining proportion of 
non-syndromic HI (Chung et al., 1959; Morton, 1991) 
Genetic HI is associated with more than 150 genes (The Molecular Otolaryngology and Renal 
Research Laboratories. The University of Iowa, 2016) of which the mutations in the connexin 
genes GJB2 and GJB6 have been shown to prevalent within European, Asian and North 
American populations (Chan and Chang, 2014; Hutchin et al., 2005; Liu et al., 2002). These 
genes have, however, been shown to be insignificant in African populations (Bosch et al., 
2014a, 2014b; Gasmelseed et al., 2004; Kabahuma et al., 2011; Trotta et al., 2011; Wonkam et 
al., 2015) and further analysis and study is necessary in order to elucidate the prevalent genes 
associated with African HI. 
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The heterogeneity of HI renders traditional molecular techniques obsolete in trying to 
determine the prevalent genes associated with African HI. Through the use of next generation 
sequencing, we may be able to determine the prevalent genes associated with African HI. Next 
generation sequencing (NGS), in particular massively multi-parallel sequencing (MPS), is a 
sequencing technique that allows the simultaneous sequencing of the entire genome, the entire 
exome or specific gene regions (Shearer et al., 2010). The various NGS techniques (whole 
genome, whole exome or targeted genome enrichment) have been used to determine the cause 
of HI in various populations (Sloan-Heggen et al., 2016; Yan et al., 2016). Targeted Exome 
Sequencing may be also an effective tools in determining the cause of the HI in some familial 
cases in African populations (Lebeko et al., 2016). However, to the best of our knowledge, no 
study has investigated the use of whole exome sequencing in revealing mutation in HI among 
Africans. 
The aim of this study is to determine the rates for putative pathogenic variants in 100 HI 
associated genes, among Cameroonian patients affected by HI, and non-hearing impaired 
controls, through the use of whole exome sequencing. The study also seeks to determine the 
genomic architecture and the evolutionary adaptation of hearing in an African population. 
 
Chapter 1.2: Definition and epidemiology of hearing impairment 
HI is so defined when an individual cannot detect sound lower than 25dB in the better hearing 
ear and is further defined as disabling when there is an inability to hear sound greater than 
40dB in an adult or 30dB in a child (WHO Media Centre, 2017).  
HI may affect one (unilateral) or both ears (bilateral) and is classified as indicated in Table 1 
according to the grade of impairment. 
 
Table 1: Hearing impairment classification 
Grade of impairment Corresponding audiometric 
ISO value 
Performance 
0 - No impairment 25 dB or better (better ear) No or very slight hearing 
problems. Able to hear 
whispers. 
1 - Slight impairment 26-40 dB 
(better ear) 
Able to hear and repeat words 




2 - Moderate impairment 41-60 dB 
(better ear) 
Able to hear and repeat words 
spoken in raised voice at 1 
metre. 
3 - Severe impairment 61-80 dB 
(better ear) 
Able to hear some words 
when shouted into the better 
hearing ear. 
4 - Profound impairment 
including deafness 
81 dB or greater 
(better ear) 
Unable to hear and understand 
even a shouted voice. 
(Adapted from http://www.who.int/pbd/deafness/hearing_impairment_grades/en/, 2017) 
 
Further classification of HI includes the age of onset (congenital, acquired, prelingual or 
postlingual), frequencies at which the HI is most pronounced (low, middle or high frequency), 
type of HI (conductive, sensorineural or mixed), the aetiology of the HI (indicative of the cause 
of loss of hearing, either genetic factors or environmental factors) (Smith et al., 2005), whether 
the HI is progressive or stable, and, lastly, whether the HI is syndromic or non-syndromic 
(Tekin et al., 2001). 
Disabling HI affects 360 million people worldwide (WHO Media Centre, 2017). The 
prevalence of HI, however, varies over population; with 1 affected individual in 500 births in 
the Middle East (Najmabadi and Kahrizi, 2014) and a 2 in 100 000 births in the Chinese 
population (Dai et al., 2007). HI occurs in 6 in every 1000 births in developing countries 
(Olusanya and Newton, 2007) with a 5.5 in 1000 births prevalence in South Africa (Swanepoel 
et al., 2009). 
 
Chapter 1.3: Normal hearing 
The ear is composed of an outer, middle and inner ear (Holme and Steel, 1999; Rȩdowicz, 
1999)and a cross section of the structure of the ear is depicted in Figure 1.1. The outer ear 
transfers sound vibrations, through the auditory canal, to the tympanic membrane which then 
vibrates (Holme and Steel, 1999). These vibrations of the tympanic membrane are then 
amplified by the ossicles (the stapes, malleus and incus) in the middle ear (Holme and Steel, 
1999; Tekin et al., 2001). This amplification by the ossicles results in the generation of waves 
in the perilymph of the cochlea resulting in movement of the tectorial membrane which 
produces a shearing motion of the hair cells (Tekin et al., 2001). This shearing movement of 
the hair cells then opens ion channels, resulting in the influx of potassium ions, causing  the 
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depolarisation of the hair cells and the release of neurotransmitters, which activate the acoustic 
nerve (the eighth cranial nerve) (Holme and Steel, 1999; Rȩdowicz, 1999; Tekin et al., 2001).  
Figure 1.2 indicates a cross section through the cochlea and Figure 1.3 indicates a schematic 




Figure 1.1: Cross section of the outer, middle and inner ear (adapted from Smith, Bale & 
White, 2005). The outer ear is indicated by the external auditory canal and tympanic 
membrane. The middle ear is represented by the malleus, incus and stapes bones. The inner 





Following the depolarisation of the hair cells, potassium ions initially exit the hair cells through 
a channel and enter the supporting cells where they passively diffuse from cell to cell through 
Figure 1.2: Cross section of the cochlea (adapted from Willems, 2000). The inner and outer 
hair cells are situated between the tectorial membrane and the basal membrane. Movement 
of the tectorial membrane results in the shearing motion that opens ion channels in the hair 
cells to depolarise the hair cells and release neurotransmitter to activate the acoustic nerve. 
Figure 1.3: Schematic diagram of a hair cell (adapted from Rȩdowicz, 1999). The diagram 




gap junctions (Tekin et al., 2001). The potassium ions will then be actively pumped back into 
the endolymph once they reach the stria vascularis and this allows the recycling of the 
potassium ions (Tekin et al., 2001). 
 
Chapter 1.4: Aetiology of hearing impairment 
Hearing impairment may be attributed to either genetic, environmental or unknown factors 
(Schrijver, 2004) and the aetiology varies from region to region, in a higher proportion of 
environmental and/or cases of unknown aetiology in Africa (Wonkam et al., 2013). Data from 
Europe and America indicates that genetic factors account for approximately 50% of congenital 
HI and environmental factors and HI of unknown cause each account for 25% of HI in 
developed countries (Schrijver, 2004).  
In developing countries, the environment contributes more cases of HI, e.g. Cameroon, where 
putative environmental causes accounted for 52.7% of HI cases (Wonkam et al., 2013). The 
environmental causes of HI may be categorized as congenital causes of HI or acquired causes 
of HI (WHO Media Centre, 2017). The congenital causes may be due to maternal infections 
during pregnancy, low birth weight of the new-born, birth asphyxia of the new-born, maternal 
drug use during pregnancy and severe jaundice in the new-born (WHO Media Centre, 2017). 
The acquired causes of HI may be due to infectious disease; such as meningitis, mumps, 
measles and rubella (Wonkam et al., 2013); chronic ear infections, blockage of the ear canal, 
injury or head trauma, excessive noise and drug use or ototoxicity (WHO Media Centre, 2017). 
The aetiology of the environmental causes of HI is heterogeneous and similar to the genetic 
causes of HI in this sense. 
 
Chapter 1.5: Genetics of hearing impairment 
Genetic HI may be classified as non-syndromic if the HI occurs without other clinical 
manifestation, whereas syndromic HI occurs when more than one clinical manifestation is 
observed (Schrijver, 2004). HI is associated with approximately 152 genes (The Molecular 
Otolaryngology and Renal Research Laboratories. The University of Iowa, 2016) and over 
1000 distinct pathogenic mutations in these genes (Shearer et al., 2011). Non-syndromic HI 
comprises 70% to 80% of genetic HI, of which 70% to 80% is a result of autosomal recessive 
inheritance (Chung et al., 1959; Morton, 1991). Autosomal dominant inheritance is responsible 
for 15% to 20%, X-linked inheritance is responsible for ~1% and mitochondrial inheritance is 




Chapter 1.5.1: Syndromic hearing impairment 
Syndromic HI occurs when the HI is accompanied by one or more clinical features (Schrijver, 
2004). This may include syndromes such as Usher Syndrome and Pendred Syndrome and these 
two syndromes will be discussed, in detail, below, as they may mimic non-syndromic HI, if 
not fully investigated. 
 
Chapter 1.5.1.1: Usher syndrome 
Usher syndrome was first reported in 1858 (Von Graefe, 1858), before been reported in 1914 
by Charles Usher (Usher, 1914) who emphasised the hereditary nature of Usher Syndrome 
(Smith et al., 1994). Usher syndrome consists of 3 different subtypes, which have differing 
severity (Lévy et al., 1997). Usher syndrome type I consists of seven subtypes (Boëda et al., 
2002) and it is associated with severe congenital HI, vestibular dysfunction and prepubertal 
onset of vision loss due to retinitis pigmentosa (Kimberling et al., 1992; Lévy et al., 1997). 
Usher syndrome type II is associated with a less severe form of HI as compared to Usher 
syndrome type I (Kimberling et al., 1992), normal vestibular function and vision loss due to 
retinitis pigmentosa (Weston et al., 1996). Usher syndrome type III is associated with 
progressive HI, as compared to congenital HI in Usher syndrome type I and type II, variable 
vestibular dysfunction, and vision loss due to retinitis pigmentosa (Weston et al., 1996). 
Usher syndrome is the most prevalent form of combined deafness and blindness, accounting 
for 50% of such cases (Petit, 2001) with a prevalence of 1 in 6000 in an American population 
(Kimberling et al., 2010). There are 15 associated loci, of which 11 correspond to known genes 
and 4 correspond to unknown genes (Van Camp & Smith, accessed May 2016 and June 2017) 
and this is indicated in Table 2.
13 
 
Table 2: Loci associated with Usher Syndrome showing known and unknown genes. 
Locus Location Gene Reference 
USH1B 11q13.5 MYO7A (Weil et al., 1995) 
USH1C 11p15.1 USH1C (Bitner-Glindzicz et al., 2000; Smith, 1992; Verpy et al., 2000) 
USH1D 10q22.1 CDH23 (Bork et al., 2001; Wayne et al., 1996) 
USH1E 21q21 Unknown (Chaïb et al., 1997) 
USHF 10q21-22 PCDH15 (Ahmed et al., 2001; Alagramam et al., 2001) 
USH1G 17q24-25 SANS (Mustapha et al., 2002; Weil et al., 2003) 
USH1H 15q22-23 Unknown (Ahmed et al., 2009) 
USHIJ 15q23-q25.1 CIB2 (Riazuddin et al., 2012) 
USHIK 10p11.21-q21.1 Unknown (Jaworek et al., 2013) 
USH2A 1q41 USH2A (Eudy et al., 1998; Kimberling et al., 1990) 
USH2B 3p23-24.2 Unknown (Hmani et al., 1999) 
USH2C 5q14.3-q21.3 VLGR1 (Pieke-Dahl et al., 2000; Weston et al., 2004) 
USH2D 3q32 WHRN (Ebermann et al., 2007) 
USH3 3q21-q25 CLRN (Ebermann et al., 2010) 
 10q24.31 PDZD7 (Joensuu et al., 2001; Sankila et al., 1995) 
(Adapted from http://hereditaryhearingloss.org, 2017)
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Chapter 1.5.1.2: Pendred syndrome 
Pendred syndrome is a syndromic HI first described in two sisters in 1896 (Pendred, 1896; 
Reardon et al., 1997) and the autosomal recessive inheritance pattern of Pendred syndrome was 
indicated in 1927 (Brain, 1927; Reardon et al., 1997). Pendred syndrome presents as enlarged 
vestibular aqueduct presenting with congenital, progressive HI which is associated with thyroid 
disease and goitre (Everett et al., 1997; Reardon et al., 1997; Sugiura et al., 2005; Yang et al., 
2009). 
The clinical features of Pendred syndrome, however, vary between individuals and within 
families (Sugiura et al., 2005). The variations may include the age of onset for the HI and 
goitre, as well as the presence or absence of vestibular dysfunction and fluctuations in the HI 
(Cremers et al., 1998). Enlargement of the aqueduct may also vary whereby some patients do 
not present with an enlarged aqueduct (Reardon et al., 1997). 
Pendred syndrome may be the most common form of syndromic HI where it may account for 
up to 10% of syndromic HI (Everett et al., 1997; Fraser et al., 1960; Reardon et al., 1997). 
Mutations in the SLC26A4 gene were initially identified as the causative mutation in Pendred 
syndrome (Everett et al., 1997). It is however now known that both digenic inheritance of 
mutations in SLC26A4 and KCNJ10 may also result in Pendred  and double heterozygosity in 
SLC26A4 and FOXI1 (Yang et al., 2009, 2007). 
 
Chapter 1.5.1.3: Other hearing impairment syndromes 
Other forms of syndromic HI include Waardenburg Syndrome (Waardenburg, 1951), Jervell 
and Lange-Nielsen Syndrome (Jervell and Lange-Nielsen, 1957)and Branchio-oto-renal 
(Asherson, 1834; Přecechtěl, 1927) amongst others. The syndromes vary according to 
phenotype, with HI as a common feature. 
Waardenburg Syndrome affects, in conjunction with the HI, the positioning of the eyes and 
pigmentation in the hair, skin and eyes and, periodically, resulting in abnormalities of the limbs 
(Hoth et al., 1993; Waardenburg, 1951) and being attributed to six known genes (PAX3, MITG, 
SNAI2, EDNRB. EDN3 and SOX10) (Attié et al., 1995; Edery et al., 1996; Hoth et al., 1993; 
Pingault et al., 1998; Sánchez-Martín et al., 2002; Tassabehji et al., 1994, 1992) and two 
unknown genes (Lalwani et al., 1994; Selicorni et al., 2002). Waardenburg syndrome type II is 
the most common form of syndromic HI in African populations (Wonkam et al., 2013). 
Jervell and Lange-Nielsen associated HI with prolongation of the QT phase of the 
electrocardiogram, increased fainting episodes due to ventricular arrhythmias and an increased 
risk of sudden death (Jervell and Lange-Nielsen, 1957; Neyroud et al., 1997) and the syndrome 
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is due to mutations in the genes, KCNQ1 (Neyroud et al., 1997)and KCNE1 (Schulze-Bahr et 
al., 1997; Tyson et al., 1997).  
Branchio-oto-renal syndrome is combined HI with branchial cleft cysts and renal abnormalities 
(Hoskins et al., 2007; Kumar et al., 2000). It has been associated with three known genes 
(EYA1, SIX5 and SIX1) (Abdelhak et al., 1997; Ruf et al., 2004, 2003) and one unknown gene 
(Kumar et al., 2000). In conjunction with Usher Syndrome and Pendred Syndrome, these three 
syndromes indicate the phenotypic and genotypic heterogeneity of HI. 
 
Chapter 1.6: Prevalent genes associated with Non- Syndromic 
hearing impairment 
The connexin genes GJB2 and GJB6 account for the highest proportion of genetic HI in 
European, Asian and North American populations (Chan and Chang, 2014; Hutchin et al., 
2005; Liu et al., 2002; Najmabadi and Kahrizi, 2014; Pandya et al., 2003). Mutations in 
SLC26A4 have also been indicated to have a relatively high proportion amongst the Caucasian 
British population where mutations within this gene account for approximately 3.5% of non-
syndromic HI cases (Hutchin et al., 2005). The prevalence of mutations in the connexin genes 
will be discussed further below with emphasis placed on their significance in African 
populations. 
 
Chapter 1.6.1: Non-syndromic hearing impairment: prevalence of GJB2 and GJB6  
Mutations in the connexin genes GJB2 and GJB6 are the most frequent cause of non-syndromic  
HI (del Castillo et al., 2002; Gasparini et al., 2000) with mutations in GJB2 present in 50% of 
cases of non-syndromic HI in Europe, North America and Asia (Chan and Chang, 2014; Liu et 
al., 2002; Najmabadi and Kahrizi, 2014; Pandya et al., 2003). The distribution of the mutations 
in GJB2 is indicated in Figure 1.4. The mutations in GJB6 are present in approximately 20% 





Chapter 1.6.2: GJB2 and GJB6 mutations are rare among Africans 
Several studies examining the prevalence of mutations in the connexin genes GJB2 and GJB6, 
in African populations, have taken place with varying sample sizes. The GJB2 and GJB6 
mutations are, however, not prevalent in the Sub-Saharan African populations (Bosch et al., 
2014a; Kabahuma et al., 2011; Wonkam et al., 2015) and this is summarised in Table 3. 
Table 3 lists nine studies that investigated the prevalence of GJB2 and/or GJB6 mutations 
within Africa populations. Four studies found that GJB6 mutations had no prevalence within 
the African context whereas only two studies found the relevance of specific GJB2 mutations 
in the Ghanaian and Moroccan populations. The other 6 studies found little significance of 
GJB2 mutations within their studied populations. The insignificance of GJB2 and GJB6 
mutations highlights the necessity of further investigation in African HI in order to elucidate 
the prevalent genes among African populations and this may be achieved through next 
generation sequencing tools. 
  
Figure 1.4: Distribution of GJB2 mutations across the world (Adapted from Chan and Chang, 
2014)The different colours indicate different GJB2 mutations, however areas in black have no 




Table 3: Frequency and type of pathogenic GJB2 and GJB6 mutations in African populations 
Population Sample 
Size 





South African 182 Exon 2 (0%) D13S1830 (0%) (Kabahuma et 
al., 2011) 
Kenyan 406 Whole gene (0%) - (Gasmelseed et 
al., 2004) 
Sudanese 183 Whole gene (2.73%) - (Gasmelseed et 
al., 2004) 
Cameroonian 180 c.424_426delTTC (0.28%) 
c.499G >A (0.28%) 
- (Bosch et al., 
2014b) 




78 c.269insT (0.64%) - (Trotta et al., 
2011) 
Ugandan 115 c.208C>G (0.43%) Exon 3(0%) 
D13S1830 (0%) 
(Javidnia et al., 
2014) 








- (Hamelmann et 
al., 2001)) 
Moroccan 116 g.35delG (21.55%) 342-kb deletion 
(0%) 
(Gazzaz et al., 
2005) 
 
Chapter 1.7: Next generation sequencing and hearing impairment 
Next generation sequencing is a technique which allows low-cost simultaneous sequencing of 
multiple genes or regions of an organism’s genome (Shearer et al., 2011; Tekin et al., 2017). 
Whole genome sequencing is the sequencing of the entire genome of an organism (Shearer et 
18 
 
al., 2010) which results in 3.2*1010 bps for analysis when working with humans (Gao and Dai, 
2014). Whole genome sequencing has recently being used to identify causative mutations in 
30, unrelated, consanguineous Pakistani families (Shafique et al., 2014). 
The entire exome of the individual’s genome, which accounts for 1% of the genome of an 
organism (Teer and Mullikin, 2010), may be screened instead of the entire genome. This is 
because approximately 85% of pathogenic mutations are within the protein coding regions of 
the DNA and/or the splice sites of the genes (Shearer et al., 2011) and it provides a cost-
effective alternative to whole genome sequencing with regard to monogenic disease. Whole 
exome sequencing, in conjunction with homozygosity mapping, has been used to elucidate the 
causative mutation which resulted in HI in a consanguineous Pakistani family (Walsh et al., 
2010). The mutation in the GPSM2 was identified by the authors, when focussing on exonic 
data from the DFNB82. The notation DFNB82 indicates that the locus is inherited in an 
autosomal recessive manner and that this is the 82nd autosomal recessive HI associated locus 
identified. This region spans 3.1Mb of chromosome 1p13.1 and it  partially overlaps with 
DFNB32 (Walsh et al., 2010). This led the authors to identify a mutation in the gene that results 
in a nonsense mutation at p.R127X (Walsh et al., 2010). Whole exome sequencing will, 
however, result in data from all the genes of the individual and this may not necessarily be a  
cost effective diagnostics approach, if the genes associated with the phenotype are already 
known, as the entire exome is targeted for sequencing and analysis (Shearer et al., 2011, 2010). 
Targeted gene enrichment analysis allows for the identification of mutations in specific genes  
(Shearer et al., 2011; Tekin et al., 2017) which have been shown to be statistically relevant to 
the biological question. This is done by designing probes that are complementary to the genes 
of interest, which is more cost effective and time effective, when compared to whole genome 
or whole exome sequencing as only the relevant genes are sequenced (Shearer et al., 2011, 
2010), provided the genes associated with the phenotype are known. OtoSeq® and 
OtoSCOPE®, MiamiOtoGenes are three tools which use targeted gene enrichment to capture 
genes associated with HI for sequencing (Shearer et al., 2011; Sivakumaran et al., 2013; Tekin 
et al., 2017). 
OtoSeq® is a targeted exome tool developed by the Cincinnati Children’s Hospital Medical 
Center (Sivakumaran et al., 2013). The tool scans 24 sensorineural HI genes, and an additional 
68 genes associated with genetic disorders that are not related to sensorineural HI 
(Sivakumaran et al., 2013). OtoSeq® was used in 2013 to elucidate the causative mutations in 
34 consanguineous Pakistani HI families (Shahzad et al., 2013). 24 mutations in 28 families 
were identified, including 11 novel mutations (Shahzad et al., 2013). 
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OtoSCOPE® or otologic sequence capture of pathogenic exons uses a target gene approach 
that use solution based target enrichment to capture targeted exons (Shearer et al., 2011, 2010). 
OtoSCOPE® forms a diagnostic panel for non-syndromic HI that targets exons of all the 57 
genes associated with HI for direct sequencing (Shearer et al., 2010).  The panel currently 
screens for mutations in 152 genes and microRNAs associated with, both non-syndromic and 
syndromic, HI (https://morl.lab.uiowa.edu/deafness, January 2017). OtoSCOPE® was used in 
conjunction with whole exome sequencing to determine the causative mutation in a 
multigenerational family of European descent (Azaiez et al., 2014). The OtoSCOPE® panel 
was initially used to screen for mutations in an affected individual in the family but the panel 
did not return any variations that could be associated with the HI phenotype in the family and 
the authors then moved to whole exome sequencing for 4 affected and 4 unaffected family 
members (Azaiez et al., 2014). A novel c.533C>T mutation was discovered in the TBC1D24 
gene which encodes a protein that may be involved in oxidative stress resistance and catalytic 
activity (Azaiez et al., 2014).  
MiamiOtoGenes uses solution based custom capture to target 146 genes, their 5’ and 3’ 
untranslated regions, and 25bp intronic flanking regions, for targeted genome enrichment, with 
the targeted regions sequenced on the Illumina HiSeq2000 platform (Tekin et al., 2017). The 
genes targeted for sequencing were selected from candidate genes discovered by the 
researchers during their research and genes available on various databases, including 
Hereditary Hearing Loss Homepage (http://hereditaryhearingloss.org), Ensembl 
(http://www.ensembl.org), and OMIM (http://www.ncbi.nlm.nih.gov/omim/) (Tekin et al., 
2017). Annotation of the variants proceeded through the use of SeattlSeq137 (Ng et al., 2010), 
Online Mendelian Inheritance in Man database (OMIM) and Human Gene Mutation Database 
(HGMD) (Stenson et al., 2009) and the platform resolved 10 of the 14 patients (71%) (Tekin 
et al., 2017). The platform was further used to resolve HI in a multi-ethnic cohort of 342 hearing 
impaired probands from South Africa, Nigeria, Tunisia, Turkey, Iran, India, Guatemala and the 
United States of America, with a resolution rate of 15% (53/342) (Yan et al., 2016). The 
platform identified 57 unique variants, accounting for compound heterozygosity in 6 
individuals; including 31 novel variants (Yan et al., 2016). The resolution rate was highest in 
the Iranian  and Turkish population (57% and 42% respectively) and lowest in the Guatemalan, 




Chapter 1.7.1: Resolution of hearing impairment in African patients using targeted 
exome sequencing 
In order to resolve ARNSHL amongst patients from SSA, OtoSCOPE® was used, recently, to 
screen African HI patients from 10 Cameroonian families, who were negative for mutations in 
GJB2, GJB6 and GJA1 using direct cycle sequencing (Bosch et al., 2014a, 2014b). This 
resulted in 12 mutations in 7 families (Lebeko et al., 2016). One family presented with 
insufficient DNA quantities for OtoSCOPE® screening and two families presented with no 
mutations in any of the 57 HI associated genes present on the OtoSCOPE® panel. 
 The failure of the panel to resolve the cause of HI within all the probands is similar to other 
studies in literature that have had varying success in using Targeted Genome Enrichment to 
resolve HI within their cohorts (Azaiez et al., 2014; Brownstein et al., 2011; Choi et al., 2013; 
Moteki et al., 2016) and this is summarised in Table 4. 
 
Table 4: Resolution rate of hearing impairment using targeted genome enrichment. 
Population Sample size n Resolution Rate 
n (%) 
Gene Study 





(Brownstein et al., 
2011) 







(Choi et al., 2013) 











Caucasian 1 0 (0%) N/A (Azaiez et al., 2014) 
 
Brownstein et al. (2011) improved the efficiency of TGE by increasing the number of genes 
screened against. They screened against 246 genes which included 80 human HI associated 
genes and 162 genes associated with HI in the mouse (Brownstein et al., 2011). Choi et al. 
(2013) combined TGE and Sanger Sequencing within their 32 patient cohort. They initially 
screened the cohort for mutations in SLC26A4, POU3F4, mtDNA and GJB2. This was 
followed by TGE, against 80 HI associated genes, of 19 probands, negative for mutations in 
the above mentioned genes and mtDNA, as well as 1 proband who was positive for GJB2 
causative mutations (Choi et al., 2013). 
The use of the TGE excluded the possibility of discovering mutations in genes that have not 
been previously associated with HI. For this reason, samples from one of the two families, who 
returned no causative mutations following OtoSCOPE® screening (Lebeko et al., 2016), were 
subjected to whole exome sequencing. Whole exome sequencing has been shown to have a 
higher resolution rate, as indicated in Table 5, and it has the potential to discover causative 





Table 5: Resolution of Hearing Impairment using whole exome sequencing 
Population Sample size n Resolution rate 
n (%) 
Genes Study 
















Asian 2 2 (100%) TMC1 (Gao et al., 
2013) 
Caucasian 3 3 (100%) TBC1D24 (Azaiez et al., 
2014) 
South Asian 1 1 (100%) GRXCR2 (Imtiaz et al., 
2014) 
 
The use of WES was capable of detecting a novel variant in the GRXCR2 gene that had only 
been associated with HI in 3 affected individuals from a Pakistani family (Imtiaz et al., 2014). 
This result showed the clinical utility in detecting causative mutations in genes that had not 
been previously associated with HI. This result combined with the insignificance of the 
prevalent and known HI genes within our population makes WES a favourable approach to 
resolving HI within the African population. 
 
Chapter 1.8: Rationale of the study 
1. The most common genes in non-syndromic HI (GJB2 and GJB6) among Europeans 
and Asians affected by HI are uncommon among people of African ancestry  
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2. The use of targeted exome sequencing capturing known HI genes has a low pick up rate 
among African patients. For example, following screening using the targeted exome 
sequencing platform OtoSCOPE®, in 2/9 families the approach did not uncover 
pathogenic mutations, which potentially indicates that the potential of discovering 
novel genes associated with HI among people of African descent. 
3. Whole exome sequencing that explores the sequencing results for all coding genes 
which may allow the identification of novel HI associated genes in African population 
samples. 
4. The use of WES data from control and HI patient populations, where there are no known 
prevalent HI genes, could establish the minor allele frequencies of pathogenic variants 
within African populations and therefore the list of genes that are more relevant in 
clinical practice to these populations. 
 
Chapter 1.10: Thesis outline 
Chapter 1:  
In chapter 1, we review extant literature regarding HI and the study of genetic HI in African 
populations. The chapter includes consideration of the prevalent genes associated with HI and 
their impact on African populations. The chapter also considers the utility of next generation 
sequencing and its impact on the resolution of the genetic causes of HI in populations that have 
utilised next generation sequencing. 
 
Chapter 2: 
Chapter 2 communicates the methodology used in the study. The chapter indicates the study 
population recruitment and inclusion. It also indicates the bioinformatics pipeline that was 
followed in order to analyse the whole exome sequencing data. The chapter concludes with the 
validation techniques utilised to validate the whole exome sequencing data. 
 
Chapter 3: 
The results from the various methodologies are indicated in this chapter. The chapter addresses 
the demographics of the study population as well as the population structure. The chapter 
indicates the results from filtering the variations determined by the whole exome sequencing 
and bioinformatics analysis. It further goes on to indicate the downstream analysis of the 
interaction of novel genes with known HI associated genes and maps their protein products in 
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the greater HI protein network. The chapter further the proportion of ancestral alleles in known 
genes among the hearing impaired and the control population as well as in the Cameroonian 
and the Democratic Republic of Congo population. The chapter concludes by indicating the 
outcome of validating the whole exome sequencing results through Sanger Sequencing. 
 
Chapter 4 
The results obtained are discussed in this chapter. The relevance of the results obtained, in 
terms of the novel variants discovered and the disparity between the filtering outcome and the 
analysis from Sanger Sequencing is taken into consideration. Practical implications of the 
protein-protein interactions, the protein network and the proportion of ancestral and derived 
alleles is considered and the limitations of the study and future perspective and indicated. 
 
Chapter 5: 
The conclusions drawn from the study are stated in this chapter. These conclusions are drawn 




Chapter 1.11: Aim and objectives 
The aim of this project is to determine the minor allele frequency and/or the carrier rates for 
variations in 172 HI associated genes in Cameroonian HI patients and controls; and 
coincidently resolve the cause of HI within the hearing-impaired patients. The project also aims 
to compare the minor allele frequencies and carrier rates between and to determine the 
proportion of ancestral and derived alleles in the patients and controls  
 
Objective 1 
The first objective is the bioinformatics analysis of whole exome sequencing data from the 
patient and control populations in order to discover variations in known HI genes. This analysis 
will be compared to other African populations available in the 1000 Genome Project. 
 
Objective 2 
The second objective is to determine the genomic architecture of HI and the evolution of 
hearing, in the population. 
 
Objective 3 
The third objective is to determine the effect of the candidate variants on protein structure and 




Chapter 2: Patients and methods 
Chapter 2.1: Ethical consideration 
Ethical approval for this study was granted by the University of Cape Town’s Human Research 
Ethics Committee (HREC 621/2017) and the Cameroon National Ethics Committee of the 
Ministry of Public Health (N°123/CNE/SE/2010). Informed written and signed consent was 
provided by study participants 18 years old or older. Informed verbal assent was provided by 
minors (younger than 18 years old) and informed written and signed consent was provided by 
the parents or guardians of the minors. 
 
Chapter 2.2: Patient recruitment and inclusion 
Chapter 2.2.1: Patient recruitment 
The patient population was recruited from various Schools of the Deaf and ENT outpatient 
clinics in Cameroon as reported in Wonkam et al. (2013). The patients were recruited from 
seven of the ten regions of Cameroon, with the intention to that this would provide a diverse 
study population and had to have HI that presented itself before the age of 15 years (Wonkam 
et al., 2013). 
The patients were examined by a medical geneticist and an ophthalmologist (Lebeko et al., 
2017), to determine the nature of the HI, and the detailed family and medical history was 
obtained from the patients, their parents and their medical records (Wonkam et al., 2013). A 
total of 582 patients were recruited into the original study (Wonkam et al., 2013), but only 18 
patients with non-syndromic HI, presenting with putative genetic cause, following an 
autosomal recessive inheritance pattern were included in this present study. 
 
Chapter 2.2.2: Inclusion and exclusion criteria 
Inclusion criteria: 
1. Patients of black-African ancestry presenting with putative non-syndromic HI 
following an autosomal recessive inheritance pattern were included in this study. The 
HI needed to be of putative genetic origin or of unknown aetiology. In addition, all the 
patients included didn’t have any causative mutations in GJB2, GJB6 and GJA1, as 
exclude with Sanger sequencing of the entire coding regions. 





1. Patients presenting with putative syndromic HI or HI due to environmental factors 
2. Presented with causative mutations in GJB2, GJB6 and GJA1 
 
Chapter 2.2.3: Control population 
The control population consisted of 130 ethnically matched individuals who do not have HI 
and do not have a family history of HI. The control population was recruited from Yaoundé 
Central Hospital and Laquintinie Hospital in Douala, both hospitals are in Cameroon. 
 
Chapter 2.3: DNA extractions and quality checks 
Patient DNA was, previously, extracted from whole blood using the modified version of the 
salting out procedure (Bosch, 2013; Miller et al., 1988) and control DNA was extracted using 
the Puregene Blood Kit (Qiagen, Alameda, CA, USA), in accordance to the manufacturer’s 
instructions (Geard, 2016); both methods are available in the appendix. The concentration of 
the extracted DNA and the quality of the extraction was determined using spectrophotometry, 
which was done using the Nanodrop ND-1000 (Thermo Fischer Scientific, Waltham, USA) 
where TE buffer was used as the blank. The spectrophotometric readings provided the 260/280 
and 260/230 readings, which were used to determine if the presence of protein and RNA 
contamination, respectively. The spectrophotometric readings also provided the concentration 
of the DNA which would be used to make working DNA dilutions. 
The integrity of the DNA was assessed using a 2% agarose gel and visualised using Sybr Safe 
(Invitrogen by Thermo Fisher Scientific, California, USA) under UV light produced by the UV 
Doc (UVItec Ltd). This gave an indication of the integrity of the DNA by indicating whether 
the DNA was fragmented, and the degree of fragmentation, or if it was intact, which has 
consequences for downstream analysis as fragmented DNA may hamper the polymerase chain 
reaction. 
 
Chapter 2.4: Whole exome sequencing  
The patient and control population were subjected to whole exome sequencing. This is 
supported by  previous data that evidenced the low pick up rates of mutation in known genes 
in populations of African ancestry with HI (Bosch et al., 2014a, 2014b; Gasmelseed et al., 
2004; Gazzaz et al., 2005; Javidnia et al., 2014; Kabahuma et al., 2011; Lebeko et al., 2017, 
2016; Trotta et al., 2011; Wonkam et al., 2015) and the large genetic heterogeneity of HI, 
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whereby over 1000 distinct mutations (Shearer et al., 2011; Sloan-Heggen et al., 2016; Tekin 
et al., 2017) in over 100 genes have been associated with HI (The Molecular Otolaryngology 
and Renal Research Laboratories. The University of Iowa, 2016). The use of whole exome 
sequencing may allow for the detection of novel mutations in genes that have not been 
previously associated with HI before. 
Whole exome sequencing of Patient and Control DNA was done by Omega Bioservices 
(Norcross, GA, USA). The DNA concentration was first quantified using the QuantiFlour 
dsDNA System on a Quantas Flourometer (Promega, Madison, WI, USA). The DNA library 
was prepared, using the Illumina Nextera Rapid Capture Exome Kit (Illumina, San Diego, CA, 
USA), by tagmenting 50ng of genomic DNA using the Nextera transposomes. The libraries 
were then hybridized with a 37M probe pool to enrich the sequences and were subjected to 
whole exome sequencing using the Illumina HiSeq 2500 (Illumina, San Diego, CA, USA) 
using a 100bp run format, with an average read depth of 30X. 18 of the 19 patients were 
successfully sequenced. 
 
Chapter 2.5: Bioinformatics analysis 
Chapter 2.5.1: Reads alignment and post-alignment quality checks 
Following sequencing, the quality of the whole exome sequencing needs to be verified prior to 
any downstream analysis. The quality control measures give an indication of how trustworthy 
each variant call may. The whole exome sequencing data was subjected to quality control 
measures using FastQC (Van Der Auwera et al., 2014) and SolexaQC++ (Cox et al., 2010). 
The sequencing read was aligned to a reference sequence, following quality control measures, 
to determine the genetic sequences of each individual. The reads were aligned to hg19, build37, 
downloaded from the UCSC database (Rosenbloom et al., 2015) using BWA (Li et al., 2008; 
Li and Durbin, 2009) with local realignment performed using the Genome Analysis Toolkit 
(GATK) software (McKenna et al., 2010).  
 
Chapter 2.5.2: Variant discovery 
The ensemble variant approach was used for variant calling approaches from the GATK3.0 
(haplotypeCaller) and SamTools (Garrison and Marth, 2012) variant callers. The final variant 
call set was obtained by combining the call sets from the two mentioned variant callers using 
VariantMetaCaller (Gézsi et al., 2015), and this indicated which variants in the exomes differed 
from the reference. 
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Chapter 2.5.3: Variant annotation and mutation prioritization 
Variant annotation was performed on the resulting VCF files that consisted of the individual 
patient VCF files, a combined file of all 18 patients and a combined file of all 105 controls and, 
lastly, a combined VCF file consisting of all the patients and controls. The variants were 
annotated in order to provide information on the presence of single nucleotide polymorphisms 
(SNPs) and if the SNPs resulted in amino acid changes and, if so, the effects of the amino acid 
change on the protein. 
ANNOVAR (Wang et al., 2010) was then used to independently perform gene based annotation 
for each of the above mentioned files in order to catalogue whether the SNPs caused protein 
coding changes and to identify the affected amino acids. ANNOVAR was used on the 
“2015Dec18”, where the population frequency for each variant was obtained from the 1000 
Genomes Project exome and targeted exon datasets (The 1000 Genomes Project Consortium, 
2015) and COSMIC (Forbes et al., 2015). Genetic function information was obtained from 
RefGene (O’Leary et al., 2016; Pruitt and Maglott, 2001) and different functional predictions 
were obtained from ANNOVAR’s ljb_all. The variants were then filtered for exonic variants 
that were considered deleterious or damaging according to 10 different functional scores; 
including SIFT (Sorting Intolerant From Tolerant) (Ng and Henikoff, 2006, 2003, 2002), LRT 
(likelihood ratio test) (Fujita et al., 2011), MutationTaster (Lubeck et al., 2012), 
MutationAssessor (Reva et al., 2011, 2007), FATHMM (Functional Analysis through Hidden 
Markov Models) (Shihab et al., 2014), RadialSVM (radial Support Vector Machine)and LR 
(Logistic Regression) (Dong et al., 2015), CADD (Combined Annotation Dependent Depletion 
) (Kircher, 2014), GERP (Cooper et al., 2005; Davydov et al., 2010), PolyPhen2 (Adzhubei et 
al., 2010), PhyloP (phylogenetic P-values) (Pollard et al., 2010) and SiPhy (SIte-specific 
PHYlogenetic analysis) (Garber et al., 2009). We additionally included conserved and 
segmental duplication sites, dbSNP code (Sherry et al., 2001) and clinical relevance reported 
in dbSNP 138 (National Center for Biotechnology Information, n.d.; Sherry et al., 2001). 
Once variant annotation was completed, possible disease-causing variants were isolated with 
the data files and this was done through filtering/mutation prioritization. The annotated datasets 
were filtered for rare variants, exonic variants, non-synonymous variants, stop codons, and 
variants with predicted functional significance, natural selection on codon, and deleteriousness 
(Li et al., 2013, 2012). We retained variants that were predicted as “Deleterious” (D), “Probably 
Damaging” (D), “Disease Causing Automatic” (A) or “Disease Causing” (D), according to 10 
functional score approaches. 
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Following annotation and variant prioritization, downstream analysis was performed on the 
combined patient VCF file and the combined control file. This allowed for the detection of 
genetic differentiation and population structure. 
 
Chapter 2.5.4: Genetic differentiation and population structure 
The population structure and genetic difference for the hearing-impaired and the control 
population was analysed. Population structure analysis was done to indicate whether the control 
and hearing-impaired population originated from the same population. The presence or absence 
has implications for the downstream bioinformatics analysis on either account population 
stratification in the case of the presence substantial sub-structure in the data. Analysis of the 
genetic difference was done to determine if there was an inherent difference in particular 
genomic region, which showed unusual differences between the control and hearing-impaired 
group. Population structure analysis was performed based on principle component analysis 
(PCA) using smartpca (Patterson et al., 2006; Price et al., 2006). The data included 186 samples 
from Yoruba (YRI) in Nigeria, 173 from Esan (ESN) in Nigeria, 280 from Gambia (GWD) in 
Western Divisions in the Gambia, 116 Luhya (LWK) in Webuye, Kenya, 112 from African 
Ancestry in Southwest US (ASW), 128 from Mende (MSL) in Sierra Leone and 123 from 
African Caribbean in Barbados (ACB) from the 1000 genomes Phase3 (The 1000 Genomes 
Project Consortium, 2015). The data also included 6 samples from the Democratic Republic of 
Congo (DRC) (unpublished data). The PCA was initially performed on the patient and control 
Cameroonian cohort. It was then performed on the merged data set of the eight African 
populations and the control and patient Cameroonian cohort. The first two components, in both 
PCAs, were plotted against each other using Genesis2. 
The genetic difference between the HI patient and control groups was investigated by 
performing a statistic test of difference to detect unusual genetic difference between the HI 
patient group and the control group from the aggregate SNP frequency at gene level (Chimusa 
et al., 2015). SNP frequency was assigned to a given gene, if the SNP was located within the 
gene or within the gene’s downstream or upstream region using dbSNP138 database. The SNP 
allele frequencies were aggregated using Fisher’s Combined Probability (Fisher, 1958). 
 
Chapter 2.5.5: Pathway enrichment analysis and protein-protein interactions 
A comprehensive human Protein-Protein Interaction (PPI) network (Chimusa et al., 2015; Wu 
et al., 2009) was used to analyse how each of the variant genes are layered in a biological 
network to allow us to extract a sub-network. The association between the variant genes in the 
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subnetwork with human phenotypes and their potential biological pathways, processes, and 
molecular functions, were examined. This was done using custom scripts in python and R (R 
Core Team, 2016) and the enrichment analysis was performed using Enrichr (Chen et al., 2013; 
Kuleshov et al., 2016) and Panther (Mi et al., 2013; Thomas et al., 2003), based on the identified 
variant genes. 
The list of candidate genes was combined with the list of 159 known HI associated genes 
obtained from Deafness Variation Database (The Molecular Otolaryngology and Renal 
Research Laboratories. The University of Iowa, 2016) and ClinVar (Landrum et al., 2016), 163 
genes in total, to perform a community network analysis. A clustering script in R’s igraph 
package (Csárdi and Nepusz, 2006) was used to produce a network plot that would allow for 
the identification of hub proteins in the sub-networks of HI genes. 
 
Chapter 2.6: Evolutionary adaptation of human hearing 
SNP ancestral alleles were downloaded from the Ensembl, a 59 comparative 32 species 
alignment (Paten et al., 2008), and further determined the presence of the SNPs in the dbSNP 
database. Our final patient and control VCF files were annotated using the VCFtools ‘fillOaa’ 
script (Danecek et al., 2011), with the ancestral allele recorded using the ‘AA’ INFO tag (“The 
1000 Genome Project Consortium Ancestral Allele Reference Sequence,” 2012). 
The ancestral allele for each SNP was computed (independently in the patient and control 
datasets), by dividing the number of times the alternative allele matched the ancestral allele 
with the number of copies of all alternative alleles across all samples at the particular SNP. The 
fraction of the derived allele is equivalent to 1 minus the fraction of the ancestral allele. 
It has been previously shown that the derived alleles are more often minor alleles (allele 
frequency less than 50%) and are more often associated with risk than ancestral alleles 
(Gorlova et al., 2012). We, therefore, investigated the relationship between the fraction of the 
derived allele and the minor allele frequency of each phenotype. To this end, the alternative 
alleles were categorised in 6 bins (0-0.05, >0.05-0.1, >0.1-0.2, >0.2-0.3, >0.3-0.4, >0.4-0.5) 
with respect to the patient and control group frequencies and the fractions of the derived alleles 
were independently computed for each bin. Furthermore, the fraction of ancestral/derived 
alleles for all known and candidate HI genes was computed. To this end, the fraction of 
ancestral/derived alleles were computed at the SNP-based level to the gene, considering all the 
SNPs located within the gene and downstream and upstream region (Chimusa et al., 2015) and 
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the Bioinformatics pipeline, including analysis of the fraction of derived and ancestral alleles 




Whole Exome Sequencing 
of 18 patients
Analysis of the quality of 
reads using FastQC and 
SolexaQC++
Alignment To hg19 using 
BWA and GATK
Variant calling performed 
using haplitypeCaller and 
SamTools with final variant 
set indicated by 
VariantMetaCaller
Variant annotation 
performed on individual 
patient, merged control, and 
merged patien and control 
VCF files using ANNOVAR
Variant filtering/mutation 
prioritization performed 
according to annotation of 
pathogenicity by 10 of the 
15 databases
Principle component 
analysis performed using 
smartpca and Genesis2
Genetic differentiation 
between the hearing 
impaired and control 




performed using python, R, 
Enrichr and Panther
Protein-proein/community 
netowrk analysis performed 
using R
Proportion of derived and 
ancestral allele performed 
by annotating combine 
patient and control VCFs 
using VCFTools 'fillOaa' 
script and computing 
proportion of ancestral 
alleles
Figure 2.6.1: Bioinformatics pipeline used to analyse whole exome sequencing data. Pipeline indicates the steps taken in the analysis of the 
whole exome sequencing in order to generate the results 
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Chapter 2.7: Validation by Sanger Sequencing 
Chapter 2.7.1: Primer Design 
Primers were designed to amplify the variants identified in VTN, RPL3L, DHRS4L2, MYO3A and MYO15A during filtering. The primers are 
described below in Tables 6. These primers are necessary for amplification of the target regions and are designed to decrease non-specific binding 
and amplification. 
 
Table 6: Properties of the primers amplifying fragments surrounding target SNPs 


















CCA GGG CAA GAC TGG AGA T 19 57.9 56.8 5 886.9 
406 






AAG CCC TGC CTG TGC TC 17 64.7 58.4 5 122.4 
420 
Reverse 
TTC TGG GAC CAT CCA GCT 
CTA 






TAG TAG GCA CAC GTA GGA 
GTT A 
22 45.5 54.5 6 823.5 
390 
Reverse 
TCT AGG AAA GCA GGG AAG 
GA 






TAC TTT CAT TGG ACC AAC 
AGG AT 
23 39.1 54.1 7 022.6 
643 
Reverse 
GCC AAA TTA TCT CTG CAC TTC 
TTA C 




GGG TCC TTC TTC TCC TCT ACT 21 52.4 55.0 6 290.1 
554 
Reverse ACT GGT GTA GCC TCT CTT CT 20 50.0 54.9 6 050.0 
 
The primers were designed by downloading the genomic sequence for each gene from Ensembl (Aken et al., 2016) and locating the region of 
interest surrounding the SNP. The region of interest was then copied into the PrimerQuest Tool, available from Integrated DNA Technologies 
website, and specifying design parameters of the primer pairs generated. 
For the primer pairs indicated in Table 6, the primers needed to amplify a region between 350 and 650bp, with a minimum of 100bp upstream and 
downstream of the target SNP, which allows the target region to be long enough for satisfactory resolution by the capillary electrophoresis. The 
primers needed to amplify between 54°C and 60°C and contain a GC content between 30% and65%, which allows the primers to bind selectively 
to the region of interest. The last parameter was that the primers needed to be between 16bp and 30bp long, which is the optimal primer length.  
The primers were then analysed for specificity to ensure that minimal non-specific binding occurs which could interfere with efficient amplification 
of the target region or with downstream analysis of the PCR products. This analysis was done by imputing the generated primers into Primer-
BLAST (Ye et al., 2012)  
The primers for VTN, RPL3L and DHRS4L2 were redesigned due to poor amplification. The primers were redesigned to specification listed above 
but a GC-clamp was incorporated into the 3’ end of the primer to assist in securing the primer to the template strand and improving amplification. 
The primers generated were check for specificity in Primer-BLAST and In-Silico PCR (Kent, 2002), based on the GRCh38/hg38 reference genome 




Table 7: Properties of the redesigned primers amplifying fragments surrounding target SNPs 














VTN Forward rs370266094 
 
TACTCCCAGTACTGTTTCCC 20 50.0 55.9  451 
Reverse TGCCTTAGGGCAAGGG 16 62.5 55.2  
RPL3L Forward rs143345186 
 
TAGCTCCTGCGCTTACCG 18 61.1 59.2  719 
Reverse CCTTGGCTGCAGTATGGG 18 61.1 57.8  
DHRS4L2 Forward rs145720846 
 
GAAAGTGATGTCAGTTCTTGGGAACTAAGG 30 43.3 63.8  570 





Chapter 2.7.2: Primer Optimization 
The PCR experiments, with the above specified primers, were optimised for the best conditions 
for the polymerase chain reactions to occur. This can be done through temperature and 
concentration gradients for the various reagents that are necessary for the reactions to occur as 
well as adjusting reaction parameters in order to optimise amplification. 
The various primer pairs were initially subjected to a temperature gradient using control DNA, 
within 5°C above and below the predicted melting temperature. A second temperature gradient 
would be run with the gradient 1°C above and below the temperature that produces the brightest 
band in the initial temperature gradient. The temperature gradients allowed the primer efficacy 
to be observed at 8 different temperature points in order to assess the best temperature for 
primer annealing in the PCR reaction. The primers amplifying the variants in MYO15A and 
MYO3A had sufficient amplification for there to be no need to run a concentration gradient to 
further optimise the primer pairs. The primer pairs amplifying the fragments in VTN, DHRS4L2 
and RPL3L3 had poor amplification coupled with non-specificity and were thus redesigned and 
the new primer pairs provided satisfactory amplification of the target fragments with no non-
specific binding. 
 
Chapter 2.7.3: Polymerase Chain Reaction and product detection 
The fragments of interest were amplified using polymerase chain reaction (PCR) in order to 
provide enough copies of the fragment of interest for sequencing. The reaction mixture 
included 16.9µl of distilled, DNase free, water (Sabax water for injections, Adcock Ingram, 
Johannesburg, South Africa); 5µl of GoTaq 5X Buffer (Promega, Madison, Wisconsin, USA); 
1µl of 5mM dNTPs (Solis Biodyne, Tartu, Estonia); 0.5µl of 20µM of the forward primer and 
of the reverse primer (Whitehead Scientific, Johannesburg, South Africa); 0.1µl of 5U/µl of 
GoTaq Polymerase (Promega, Madison, Wisconsin, USA); and 1µl of 100ng DNA. 
This PCR was performed by initially denaturing the genomic DNA into single stranded DNA 
by heating it to 95°C for 3 minutes. This was followed by 35 cycles of denaturing the DNA by 
heating it to 94°C for 30 seconds, followed by annealing the primers to the DNA by lowering 
the temperature to 61°C for 40 seconds. The primers were then elongated, and the DNA 
transcribed, by increasing the temperature to 72°C for 1 minute. Following the cycles of 
amplification, the fragment length for all the fragments was ensured by allowing the fragments 




Chapter 2.7.4: PCR clean-up 
The product of the PCR reactions may be cleaned prior to sequencing to eliminate 
unincorporated dNTPs and to degrade the primer pairs and single stranded DNA. This was 
done by incubating 8.9µl of the PCR product with 1µl of Thermosensitive FastAP (Thermo 
Fischer Scientific, Waltham, USA) and 0.1µl of Exo1 endonuclease (Thermo Fischer 
Scientific, Waltham, USA) at 37°C for 1 hour. This was followed by inactivating the enzymes 
by raising the temperature of the reaction to 75°C for 15 minutes. 
The Thermosensitive FastAP will degrade the excess dNTPs in the PCR product. The Exo1 
endonuclease will degrade single stranded DNA and the primers. 
 
Chapter 2.7.5: Direct Cycle Sequencing and Capillary Electrophoresis 
The cleaned PCR products were subjected to direct cycle sequencing. This allows the DNA 
sequence to be determined for each fragment determined through the use of chain termination 
sequencing and capillary termination as developed by Sanger, Nicklen & Coulson (1977). 
Sequencing was performed using the BigDye ® Direct Cycle Sequencing Kit (Thermo Fischer 
Scientific, Waltham, USA). 2µl of the PCR cleaned product were incubated with 1µl BigDye® 
Terminator Mix, 2µl BigDye® Dilution Buffer, 0.5µl of the forward or reverse primer and 
4.5µl dH2O. The reaction was run with an initial denaturation step at 96°C for 5 minutes. This 
was followed by 30 cycles of denaturation at 96°C for 30 seconds, primer annealing at 50°C 
for 15 seconds and strand elongation at 60°Cfor 4 minutes. 
The sequencing product was cleaned up by precipitating the sequencing product, in 50µl 100% 
(absolute) ethanol and 2µl sodium acetate, with vortexing to mix, overnight at -20°C. The DNA 
was pelleted out of the solution by centrifuging at 10 000g for 10 minutes. The supernatant was 
discarded whilst carefully ensuring not to disturb the pellet of DNA. 50µl of 70% ethanol was 
then used to resuspend the DNA pellet using vortexing, whereby these steps allow the DNA to 
precipitate out of solution and to be concentrated in preparation for capillary electrophoresis. 
The DNA was once again pelleted out by centrifuging at 10 000g for 10 minutes. The 
supernatant was once again discarded, and the pellet was allowed to airdry for 2 hours before 
it was resuspended in 10µl HiDi Formamide and the run on the 3130xl Genetic Analyzer ABI 
Prism (Applied Biosystems) capillary electrophoresis. 
 
Chapter 2.7.7: Sequencing Results Analysis  
The sequencing results from capillary electrophoresis were processed using the Sequencing 
Analysis Software (Applied Biosystems). The software performed the base calling from the 
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capillary electrophoresis data and, thus providing the DNA sequence, for each of the samples 
subjected to capillary electrophoresis. The DNA sequences were then analysed/visualised 
using the Unipro UGENE (Golosova et al., 2014; Okonechnikov et al., 2012).  
 
Chapter 2.7.8: BAM file analysis  
The sequencing results obtained by Direct Sanger Sequencing presented were discordant with 
the result from bioinformatics analysis of the whole exome sequencing with regard to the 
putative causative mutations in the patients. Due to this discordance, the BAM files for each of 
the putatively resolved was viewed using Integrative Genomics Viewer (IGV) software 
(Robinson et al., 2011; Thorvaldsdottir et al., 2018).The SNP position for rs140301218,in 
MYO3A, rs138861831, in MYO15A, and rs14503583, in COL9A3, was determined using 
Ensembl GRCh37 (Flicek et al., 2014; Zerbino et al., 2018) and the SNPs were compared to a 
patient, or patients, who were indicated to not carry the variations by bioinformatics analysis 
as well as the hg19 reference sequence.  
 
Summary of bioinformatics methodology 
Ethics approval was granted for this study by the Human Research Ethics Committee if the 
University of Cape Town. Nineteen hearing impaired patients and 130 ethnically matched 
controls from the Cameroonian population were included in this study. Patients were 
previously recruited from Schools of the Deaf and ENT out-patient clinics if they presented 
with HI that presented before 15 years of age. Patients included in this study had to present 
with putative non-syndromic HI that was not a result of causative mutations in GJB3, GJB6 
and GJA1. 
DNA samples from the patient and control populations were subjected to whole exome 
sequencing, following successful integrity checks. The whole exome sequences were then 
subjected to quality checks and aligned to the reference hg19 genome assembly. Variant calling 
was performed, and the variants were annotated and filtered to determine putative causative 
mutations resulting in HI in the patients and variations that may putatively modify the HI 
phenotype that were present in the entire Cameroonian population. 
The population structure of the Cameroonian population was analysed through the use of 
principal component analysis by comparing the patient and control population to other African 
populations and by comparing the patient and control population to one another. The patient 
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and control population were also analysed to identify the presence of significant genetic 
difference between them. 
The variations discovered in the novel genes were included into a list of known HI associated 
genes and these genes were used to determine protein-protein interactions, enrichment analysis 
and pathway analysis. This would generate an interaction plot and a network plot which 
incorporates the newly associated genes, and this may provide possible insight into the manner 
by which they affect HI. 
Haplotype analysis was performed on the patients segregating the three novel, putative 
causative mutations, which could cumulatively resolve the HI in 50% of the patient population. 
The analysis would allow for insight into whether the variations are founder mutations in the 
Cameroonian population. 
Analysis of the proportion of derived and ancestral alleles concluded the bioinformatics 
methodology. This analysis was done to determine the proportion of ancestral, and conversely 
derived, alleles in the patient and control populations, as well as in the Cameroonian population 
and select samples from the Democratic Republic of Congo. The analysis contrasted the 
proportion of ancestral alleles within the patient and control population at various minor allele 
frequencies, as well as indicating the proportion of ancestral alleles in genes that may be 
significant in HI in the Cameroonian and Congolese populations. 
 
Summary of molecular methodology 
The variants discovered in the whole exome sequencing and subsequent bioinformatics 
analysis were validated through direct cycle sequencing. This was done by designing primers 
specific to the genomic sequence surround the variants of interest. The five primer pairs were 
optimised to their optimal experimental conditions through a temperature gradient and these 
conditions were utilised to amplify the target regions surrounding the five variants. 
The PCR products were cleaned up in preparation for sequencing by degrading unincorporated 
dNTPs and the primers from the PCR reaction. This was followed by direct cycle sequencing 
of the PCR products using the chain termination technique. The sequencing product was then 
up by precipitating with 70% ethanol and sodium acetate overnight which was followed with 
by centrifugation of the mixture to pellet out the DNA. The supernatant was discarded, and the 
DNA was re-suspended in 100% ethanol and subjected to centrifugation once again, to allow 
the concentration of the DNA prior to electrophoresis. The supernatant was discarded and the 
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Chapter 3: Genomics architecture of non-syndromic 
hearing impairment results 
Chapter 3.1: Patients clinical information 
The patient population consisted of an almost equal distribution of male and female 
participants. The mean age of the population was 13 years old (± 4.48 years). The youngest 
individual in the cohort was 6 years old and the oldest individual was 27 years old. The majority 
of the HI presented as congenital (88.9%) and profound HI (88.9% in right ear and 83.3% in 
left ear) and the demographics of the population are summarised in Table 6 
 







Gender Male 10 55,56 
Female 8 44,44 
Age of Onset Congenital/Prelingual 16 88,89 
Prelingual 2 11,11 
Degree of hearing 
impairment – Left 
Severe 1 5,56 
Profound 16 88,89 
No Data 1 5,56 
Degree of hearing 
impairment – Right 
Severe 2 11,11 
Profound 15 83,33 
No Data 1 5,56 
Transmission Familial 12 66,67 
Sporadic 6 33,33 
Mechanism Sensorineural 15 83,33 
Not Determined 3 16,67 
Consanguinity Yes 0 0,00 
No 18 100,00 
Endogamous Population Yes 7 38,89 




Table 6 also indicates that the majority of the HI was sensorineural (83.3%) and familial HI 
(66.7%). None of the patients were from consanguineous families, though 7 (39%) patients 
were from endogamous populations.  
 
Chapter 3.2: Variant filtering 
Variant filtering was performed on both the individual datasets and the combined patient 
dataset. Filtering variants in the combined patient dataset resulted in population specific 
variants, which were present in the merged control and patient population, which were 
classified as Damaging/Deleterious by 10 of the 15 annotation databases. The variants 
discovered are indicated below in Table 9, population specific variants, and Table 10, 
individual/clinical variants. 
 
Table 9: Candidate variants discovered at the population level of the Cameroonian merged 
patient and control population 






FOXD4L6 9p11.2 rs71246017 G/C Non-
synonymous 
-* -* 
DHRS4L2 14q11.2 rs145720846 G/A Non-
synonymous 
c.134G>A p.Gly45Asp 
RPL3L 16p13. rs143345186 C/T Non-
synonymous 
c.151G>A p.Ala51Thr 




Data for the SNP rs71246017 in FOXD4L6 is not available. All the variants, including the 
rs71246017, occur in the exonic region of the genes and all are classified as non-synonymous. 
All four genes have not been previously associated with HI and each individual in the merged 
dataset needed to have the variant for it to filter out.
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Variant filtering indicated putative pathogenic variants, indicated in Table 10, in MYO3A, 
MYO15A and COL9A3 genes which may result in non-syndromic, autosomal recessive 
phenotype observed in the patients. The variants observed in the genes are most probably 
pathogenic, however, rs138861831 in MYO15A has conflicting clinical annotation in ClinVar 
whereby it has been annotated as likely benign (1 study) and with uncertain significance (2 
studies) in three studies. COL9A3 is typically associated with Stickler Syndrome, however, 
there is a study associating a recessive mutation in COL9A3 to non-syndromic HI (Asamura et 
al., 2005). The most likely variation associated with HI in the patient population is the variation 
in MYO3A whereby the gene has been previously associated with HI in an African-American 
family (Grati et al., 2016). 
Variant filtering indicated variations in USH2A, MYO1A and HSD17B4, as shown in Table 11. 
The variations in these genes are unlikely to be causative mutations in the patients as MYO1A 
has been excluded as a HI associated gene in several prior studies (Eisenberger et al., 2014). 
The variation in USH2A has been indicated to be benign by ClinVar and USH2A is associated 
with Usher Syndrome Type 2A (Eudy et al., 1998; Kimberling et al., 1990). Finally, the 
HSD17B4 is associated with Perrault syndrome (Jenkinson et al., 2013; Perrault et al., 1950; 
Pierce et al., 2010)and D-bifunctional protein deficiency (Grønborg et al., 2010; Suzuki et al., 
1994; Watkins et al., 1989), both syndromic conditions that present with HI, therefore the 
variations in HSD17B4 are most likely not causative mutations in the patients as the phenotype 





Table 10: Candidate variants found in 9/18 Cameroonian patients affected by Non-Syndromic Hearing impairment, with whole exome sequencing 
and analysis of 172 known genes£ 
£Exonic. nonsynonymous variants that were considered deleterious/damaging according to 14 different functional scores of annotation databases, 
including SIFT, Polyphen2_HDIV, Polyphen2_HVAR, Likelihood ratio test, MutationTaster, MutationAssessor, FATHMM, fathmm-MKL, 
RadialSVM, LR, CADD, PROVEAN, MetaSVM and MetaLR, as previously reported.8 
Abbreviations Families’ Pedigrees, SP: simplex; MP: multiplex family; SNP: Single Nucleotide Polymorphism; ExAC: Exome Aggregation 
































c.C424T p.H142Y 0.0026 0.0007 0 0 














0.0083 0.0003 0 0 






c.G406A p.G136S 0 0.001 0 0 
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Table 11: Candidate variants discovered in individual patients in Genes that are unlikely to explain the HI phenotype in our patients 
































































































Chapter 3.3: Population structure 
The principal component analysis (PCA) was performed on the Cameroonian population, 
consisting of both patients and controls, with other African populations and on the 
Cameroonian patients and control population solely. The PCA, in Figure 3.3.1, indicates that 
the Cameroonian population clusters together in the bottom left corner. The populations 
represented in the PCA, from Phase 3 of the 1000 genomes project, are the Yoruba (YRI) and 
Esan (ESN) from Nigeria, individuals from the West Divisions of Gambia (GWD), the Luhya 
from Webuye in Kenya (LWK), individuals of African Ancestry from the Southwest of the 
USA (ASW), the Mende in Sierra Leone (MSL) and individuals of African Caribbean from 
Barbados (ACB). Six individuals from the Democratic Republic of Congo (DRC) were also 
included in the PCA. 
 
Figure 3.3.1: PCA comparing Cameroonian population with other African 
populations with key. The plot indicates the distribution of the Cameroonian population 
when compared to individuals of African ancestry in populations from Democratic 
Republic of Congo, Nigeria, the Gambia, Kenya, Barbados and the United States of 
America. The Cameroonian population clusters in the lower left corner of the plot with 
the Congolese population interspersed within the cluster. The key alongside indicates 
which symbol correspond to which population in the PCA. 
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The PCA in Figure 3.3.2 indicates the structure of the Cameroonian population, which has a 
distinct cluster in the lower left corner of the PCA. The five of the six individuals from the 
DRC population are interspersed within the Cameroonian population with only one individual 
clustering with the Kenyan (LWK) population. 
A second PCA plot compares the patient and control Cameroonian population to one another. 
The PCA, Figure 3.3.2, shows the two populations dispersed in the plot. Neither the control 
nor the patient population forms a distinct cluster. 
 
 
Chapter 3.4: Genetic differentiation 
Genetic differentiation between the control and patient populations was determined by 
analysing the unusual difference of the patient and control populations’ aggregated SNP 
frequencies. This was done using Fisher’s combined probability and the results are summarised 
in Table 12. 
  
Figure 3.3.2: PCA plot of the Cameroonian patient and control populations with key. 
The plot indicates the diversity of the Cameroonian patient and control population which 
fail to form distinct clusters in the PCA.  
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Table 12: Identified genetic difference between the Patient and Control populations. 






PRDX4 0.2109 0.2618 2.65E-31 
PRKACA 0.2716 0.3211 9.71E-30 
CBX1 0.2242 0.2726 1.83E-28 
COPS5 0.2908 0.2488 4.35E-22 
PRKCB 0.2540 0.2916 4.52E-18 
GLUD1 0.2251 0.2538 2.36E-11 
CRADD 0.2571 0.2853 4.66E-11 
ITGB6 0.2426 0.2687 1.11E-09 
CKS2 0.2500 0.2753 3.40E-09 
FGF2 0.2376 0.2623 8.16E-09 
IGFBP5 0.2561 0.2799 2.68E-08 
RHOXF1 0.2655 0.2422 4.51E-08 
ITGA8 0.2559 0.2770 6.81E-07 
AMPH 0.2404 0.2606 1.91E-06 
PVR 0.2336 0.2515 2.43E-05 
SERPINE1 0.2513 0.2360 3.01E-04 
RPL13A 0.2585 0.2730 5.66E-04 
VTN 0.2601 0.2457 6.14E-04 
ADH5 0.2346 0.2209 1.16E-03 
ADTRP 0.2690 0.2816 2.77E-03 
TGFB1 0.2553 0.2428 2.84E-03 
PRKCA 0.2598 0.2710 7.42E-03 
RPL3L 0.2577 0.2487 3.13E-02 
G3BP2 0.2306 0.2396 3.23E-02 
ETV7 0.2570 0.2657 3.84E-02 
PLAUR 0.2668 0.2593 7.45E-02 
IGF2 0.2707 0.2636 9.14E-02 
POMC 0.2874 0.2937 1.31E-01 
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HGF 0.2595 0.2656 1.49E-01 
CSNK2A1 0.2723 0.2663 1.54E-01 
ITGB3 0.2738 0.2793 1.96E-01 
KNG1 0.2458 0.2511 2.19E-01 
TGFB2 0.2628 0.2583 2.93E-01 
GEM 0.2536 0.2581 2.97E-01 
TNFRSF11B 0.2372 0.2329 3.05E-01 
ITGB8 0.2525 0.2563 3.75E-01 
LACRT 0.2732 0.2770 3.75E-01 
*SIX1 0.3040 0.3078 3.77E-01 
EGF 0.2376 0.2340 3.96E-01 
PRKCG 0.2451 0.2477 5.53E-01 
CD247 0.2644 0.2661 7.09E-01 
VEGFA 0.2628 0.2614 7.47E-01 
UBC 0.2681 0.2676 9.20E-01 
FGG 0.2181 0.2185 9.41E-01 
All genes above the red line have significant genetic difference between the patient and control 
population. Genes with an asterisk (*) have been previously associated with HI. 
 
The aggregated SNP frequencies was analysed in 44 genes for significant genetic difference in 
the patient and control population. 25 genes indicate significant genetic difference between the 
two populations (at p<0.05). One gene, SIX1 (MIM:601205), has been previously associated 
with HI, but it is shown that there is no significant difference between the patient and control 
population. 
 
Chapter 3.5: PPI analysis and enrichment analysis 
Filtering variants resulted in population specific variants listed in Table 9. These variants have 
not been previously associated with HI, and as such, were queried in a protein-protein 
interaction network to identify the interactions of their protein products with other HI 
associated protein. 
Figure 3.5.1 indicates the protein-protein interactions associated with VTN, RPL3L, FOXD4L6 
and DHRS4L2, as well as the associated pathways and molecular functions. The protein 
products of VTN and RPL3L are associated with 42 pairings/interactions, with FOXD4L6 and 
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DHRS4L2, indicating no interactions with other HI associated proteins, as indicated in Figure 
3.5.1A. The interactions were queried in the Enrichr database which indicated the major 
pathways associated, which includes osteoclast differentiation, as indicated in Figure 3.5.1B. 




Chapter 3.6: Community network analysis 
The candidate population genes, in Table 8, were combined with 159 known HI associated 
genes, present on the ClinVar database (Landrum et al., 2016) and the Deaf Variation Database 
(The Molecular Otolaryngology and Renal Research Laboratories. The University of Iowa, 
2016) to perform the community network analysis. The community network analysis provided 
eight protein subnetworks which had 10 hub proteins as indicated in Figure 3.5.2A and the 
associated pathways and molecular functions are indicated in Figure 3.5.2B and Figure 3.5.2C 
respectively. 
Figure 3.5.1: Reconstituted hearing impairment PPI network including enrichment 
analysis of the associated pathways and molecular functions. Figure 3.5.1A indicates the 
reconstituted PPI network including VTN and RPL3L3 and other hearing impairment proteins. 
Figure 3.5.1B indicates the associated biological pathways and Figure 3.5.1C indicates the 
molecular functions associated with the network. 
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Five of the 10 hub proteins, ACTB, MITF, SSCTG1, MYH9, and ATP2B2, are known HI 
associated proteins, whereas the other hub proteins, UBC, SRC, YWHAZ, KIAA010, and 
VTN, have not. The entire network is centred around the UBC protein which is connected to 
the proteins in the yellow subnetwork as well as all the other networks. 
The entire community network is associated with focal adhesion pathway as well as regulation 
of the actin cytoskeleton, indicated in Figure 3.5.2B. The abundant molecular processes 





Figure 3.5.2: Community 
network analysis of the 
combined hearing 
impairment associated 
proteins and the 
candidate proteins 
identified. The network in 
Figure 3.5.2A indicates 
eight subnetworks, centred 
around UBC, with 10 hub 
proteins including UBC. 
The network is associated 
with regulation of the actin 
cytoskeleton and focal 
adhesion pathways, Figure 
3.5.2B, and with binding 
and catalytic activity 




Chapter 3.7: Evolutionary adaptation of human hearing 
The proportion of ancestral and derived alleles were computed for the HI associated genes 
using custom scripts. This proportion was analysed within the patient and control population, 
indicated in Figure 3.7.1, and in the control Cameroonian population and the DRC Sickle Cell 
Disease (SCD) population, that did not present with HI, indicated in Figure 10. In both figures, 
the proportion of derived alleles is equivalent to 𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑑𝑒𝑟𝑖𝑣𝑒𝑑 𝑎𝑙𝑙𝑒𝑙𝑒 = 1 −
𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎𝑛𝑐𝑒𝑠𝑡𝑟𝑎𝑙 𝑎𝑙𝑙𝑒𝑙𝑒. 
It is shown in Figure 3.7.1 that the patient population has a decreased proportion of ancestral 
alleles at low minor allele frequencies (0.0 to 0.1), as compared to the control population. This 
proportion of ancestral alleles increases at higher minor allele frequencies, such that the control 
population has a decreased proportion of ancestral alleles at the higher minor allele frequencies. 
 
 
The proportion of ancestral alleles in the Cameroonian control population and the SCD 
population from the DRC is indicated in Figure 3.7.2. The proportions of ancestral alleles vary 
Figure 3.7.1: Proportion of ancestral alleles in the Cameroonian patient and control 
population. The patient population, denoted HL in the figure, has a lower proportion of 
ancestral alleles, and conversely a higher proportion of derived alleles, at low minor allele 
frequencies (between 0.0 and 0.1) as compared to the control population. The proportion of 
ancestral alleles in the patient population is greater at minor allele frequencies about 0.15, 
when compared to the control population. 
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for various genes, but notably, both populations indicate a low proportion of ancestral alleles 
for GJB2, which translates into a high proportion of derived alleles within both populations.  
 
 
Chapter 3.8: Validation 
The candidate variants were validated through the use of Direct Cycle, or Sanger, Sequencing 
of each patient. Sequencing analysis of the patients indicated that the three individuals 
purported to have the rs140301218, in MYO3A, do not carry the variation and as such, the 
variation is most likely a false positive in this individual. A similar occurrence was observed 
for rs138861831, in MYO15A, in the four individuals purported to carry the variation, whereby 
Sanger sequencing indicated that the individual did not carry the variation observed in the 
whole exome sequencing and subsequent bioinformatics analysis. The electropherograms for 
individual CAM119 and an unrelated individual negative for the variation are indicated in 
Figure 3.7.2: Proportion of ancestral and derived alleles in hearing impairment 
associated genes in the Cameroonian control population and a Democratic Republic of 
Congo Sickle Cell Disease population. The DRC SCD population does not present with 
hearing impairment and the figure illustrates the variation in the proportion of ancestral 
alleles in between two African populations. 
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Figure 3.8.1, for comparison. Similarly, the electropherograms for individual CAM076 and an 





Figure 3.8.1: Electropherogram for CAM119 and an unrelated individual. 
Electropherogram A) indicates the DNA sequence for individual CAM119, with the 
SNP position highlighted. CAM119 is homozygous for the CC allele and does not carry 
the T allele. Electropherogram B) indicates the DNA sequence for an unrelated 
individual, also with the SNP position highlighted. The individual also carries the 







Figure 3.8.2: Electropherogram for CAM076 and an unrelated individual. A) 
Electropherogram A) indicates the DNA sequence for CAM076, with the SNP position 
highlighted. CAM076 is homozygous for the CC allele and does not carry the T allele. 
Electropherogram B) indicates the DNA sequence for an unrelated individual, with the SNP 




CAM103, oddly enough, presented with two differing genotypes. The individual was shown to 
carry the wildtype C allele in an initial round of sequencing, which was followed by the 
individual presenting with an A allele in the second round of sequencing. This discrepancy is 
indicated in Figure 3.8.3. 
 
 
The results from the Sanger Sequencing were confirmed by viewing the respective SNPs  in 
the individual patient BAM files, in IGV. This was additionally done for the two patients 
harbouring the rs14503583, in COL9A3. The analysis indicates the absence of all the identified 
clinical SNPs in all 9 patients that were purported to harbour them and this is indicated in 
Figures 3.8.4, Figure 3.8.5 and Figure 3.8.6 below. Reads for each of the SNPs for each person 
for MYO3A and MY015A were above 30X, with the highest read depth being 58X. Read depth 
for COL9A3 for each of the patients was above 10X but below 20X. 
A) 
B) 
Figure 4.8.3: Sanger Sequencing discrepancy. Sequencing of the same variant in the 
same patient sample resulted in a discrepancy in the bases called for rs140301218. The 




The analysis of the BAM files, furthermore, addressed the discrepancy in the sequencing results 




Figure 3.8.4: BAM file view forMYO3A sequences. The BAM file indicates the 3 supposed MYO3A patients, 
CAM78, CAM103 and CAM119, as well as two control patients, CAM116 and CAM117. The SNP of interest 
is shaded in grey, in the patients as well as one control individual, as are other nucleotides in the BAM files 
indicating that the SNP in the patients and the particular control individual is homozygous wildtype. The SNP 





Figure 3.4.5: BAM file view of MYO15A sequences. The BAM files indicate the four purported MYO15A 
patients, at the top, CAM115, CAM167, CAM075 and CAM76, and one control individual, CAM014. The 
SNP of interest for that the patients were indicated to carry is shaded in grey, similarly to the control individual. 
This shading indicates that the nucleotide at that position is the same as the reference sequence 
Figure 3.8.6: BAM file view of COL9A3 sequences. The BAM files indicate the two purported COL9A3 
patients, CAM104 and CAM168, and a control individual, CAM51. The SNP of interest is shaded in grey in 
the two patients and the control patient, which indicates that the nucleotide at that position is the same as in 
the reference sequence. 
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The results provide indicate that the causative mutations resulting in HI were resolved for 0% 
of the patient population which is extremely low. 
 
Summary of results 
The patient population consisted of 18 hearing impaired individuals, of which the mean age of 
the population was 13 years old. 10 individuals of the population were male, and the majority 
of individuals were profoundly deaf in both the left and the right ear. The HI was familial in 
12 of the individuals, with sensorineural HI contributing to the HI in the majority of the 
patients. None of the patients were from consanguineous families but seven of the patients were 
from endogamous populations. 
Putative protein and function changing variants were discovered at a population level in VTN, 
RPL3L3, FOXD4L6 and DHRS4L2 in the merged patient and control population. These 
population specific genes have never been associated with HI before. Variants putatively 
associated to the HI were found in 11 of the 18 patients were identified in MYO3A, MYO15A, 
USH2A, COL9A3, MYO1A and HS17B4, with some individuals possessing more than one of 
the putative causative variants; these variants are all novel, but unconfirmed by Sanger 
sequencing and BAM files analysis.   
Population structure was analysed using principal component analysis that revealed some 
homogeneity, as the PCA indicated that the patient and control populations originate from one 
population group when compared to other African populations and each other.  Further analysis 
determined the presence of genetic difference in 44 genes; among them, 25 genes, including 
VTN and RPL3L, displayed significant genetic difference between the patients and control 
populations. 
The newly identified population specific genes variants were incorporated into a list of known 
HI associated genes and analysis of the interaction in their protein products was performed. 
VTN and RPL3L were shown to interact with 42 other proteins, with RPL3l interacting with 2 
proteins and VTN interacting with 40. The interactions were shown to be significantly 
associated with osteoclast differentiation and the bulk of the molecular activity included 
binding and catalytic activity. 
The protein network was reconstituted to incorporate the candidate population specific 
variants, and this indicated that VTN was a hub protein of one of the eight protein networks, 
where this role is shared with ATP2B2. The protein network is centred around UBC and it is 
significantly associated with focal adhesion and regulation of the actin cytoskeleton. The bulk 
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Chapter 4: Discussion and perspectives 
Chapter 4.1: Originality of study and general comments 
HI is a common sensory disorder affecting 360 million people worldwide, of which the highest 
incidence of HI is within developing countries such as the countries in Africa (WHO Media 
Centre, 2017). Despite the high incidence of HI within African countries, few studies have been 
performed on African populations and the prevalent genes associated HI within African 
populations still needs to be determined (Lebeko et al., 2017, 2016; Trotta et al., 2011). 
Furthermore, the majority of studies focus on the prevalence of the connexin genes, GJB2 and 
GJB6, which have been repeatedly shown to be of negligible significance within the African 
context (Gasmelseed et al., 2004; Javidnia et al., 2014; Kabahuma et al., 2011; Lasisi et al., 
2014; Trotta et al., 2011). 
This study aspired to remedy the deficit by attempting to determine the prevalent genes 
associated with HI in a Cameroonian population. To the best of our knowledge, this is the first 
study to use whole exome sequencing to study HI within an African population. The study has 
also identified specific population protein changing variants in VTN, DHRS4L2, FOXD4L8, 
and RPL3L, which may have possible modifier action in the HI phenotype, owing the critical 
hub roles in their protein-protein in interactions with multiple known HI genes. These findings 
are novel and deserve to be explored in other African populations.  The association between 
VTN, RPL3, FOXD4L6, and DHRS4L2 and HI was, furthermore, studied in terms of its impact 
on the HI network and what role each of the protein products may play in the network. This 
information and the interaction of the protein products with other HI associated genes is a step 
forward in determining the action of these proteins in HI. 
Exceptionally, in the present study, further analysis allowed the determination of the proportion 
of derived and ancestral alleles within the Cameroonian population. This analysis is the first 
report to our knowledge, to explore such approach in hearing loss. Data indicates the hearing-
impaired patient population carried a higher proportion of derived alleles in know HI genes, at 
low minor allele frequencies; possibly indicating, the interactive modifiers capacities of 
multiple HI genes, or alternatively, the polygenetic nature of HI in some patients. The 
proportion of ancestral and derived alleles was contrasted in the Cameroonian and the 
population from the Democratic Republic of Congo and it indicated that the variations that may 
result in HI in the one population may not be the same variations that result in HI in the other 
population.  Due to this, it is necessary to determine the causative variants resulting in disease 
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in multiple populations independently, to capture the full picture of genetic heterogeneity of 
hearing loss among Africans.  
 
Variants discovered in COL9A3, MYO3A and MYO15A have yet to be described in literature, 
and, cumulatively, putatively could have account for HI in 9 of the 18 patients, but were not 
confirmed by Sanger sequencing, nor the BAMs file analysis. This may reflect the current 
difficulty of inferring variant deleteriousness in African population, whose exomes are not yet 
well represented in Exome databases; a call for corrective action to global scientific community 
to remedy this.  
. 
 
Chapter 4.2: Candidate clinical variants 
Putative causative mutations were discovered in MYO3A, MYO15A, USH2A, COL9A3, 
MYO1A and HSD17B4. The six genes have been previously associated with HI, with the 
USH2A, COL9A3 and HSD17B4 been associated with syndromic HI. 
USH2A (MIM:276901), encoded at position 1q41, is associated with Usher Syndrome Type 
IIA, which is congenital, mild HI and prepubertal onset of vision loss due to retinitis 
pigmentosa (Eudy et al., 1998; Kimberling et al., 1990), as indicated in Chapter 1.5.1.1. The 
phenotype associated with this gene suggests that the gene may not be the causative mutation 
within the patients that carry the variation, as the patients have non-syndromic HI rather than 
syndromic HI. Furthermore, the variation, rs111033481, is indicated to be benign in the 
ClinVar database (Landrum et al., 2016). For these particular patients, further analysis will be 
necessary to identify the variation that results in the HI. 
HSD17B4 (MIM:601860), encoded at position 5q23.1, is associated with Perrault syndrome 
(MIM:233400) and D-bifunctional protein deficiency (MIM:261515). Perrault syndrome was 
initially described as Turner Syndrome presenting with deaf-mutism by Perrault, Klotz & 
Housset (1950). The syndrome presents as sensorineural HI in both males and females, 
accompanied by premature ovarian failure in females (Jenkinson et al., 2013; Pierce et al., 
2010). Additional clinical features may include cerebellar ataxia, peripheral neuropathy and 
learning difficulties (Jenkinson et al., 2013) though the syndrome is clinically and genetically 
heterogeneous as it may result from variations in several genes (Chatzispyrou et al., 2017; 
Jenkinson et al., 2013; Pierce et al., 2013, 2010). Conversely, the gene is associated with D-
bifunctional protein deficiency (MIM:261515) which presents with a severe phenotype, that 
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includes early onset hypotonia and seizures and facial abnormalities (Grønborg et al., 2010; 
Suzuki et al., 1994; Watkins et al., 1989). The severe phenotype associated with pathogenic 
variations in this gene is not demonstrated within the Cameroonian patient population, whereby 
all patients were evaluated by a qualified medical geneticist and they presented with no 
additional clinical features above the HI, and as such the possibility of this gene being the 
causative mutation for the HI within the patients who carry the variation is highly unlikely and 
further analysis will be necessary to determine the causative mutations in these patients. 
MYO1A, encoded on 12q13.3, has been previously associated autosomal dominant HI, 
indicated as DFNA48. The gene was associated with autosomal dominant HI in an Italian 
cohort (D’Adamo et al., 2003; Donaudy et al., 2003). The role of MYO1A in HI was challenged 
by Eisenberger et al. (2014) who indicated that other variations in other genes are responsible 
for HI in purported DFNA48 cases of HI. As such, the variation in MYO1A was not considered 
to be the cause of HI in the patients who carry the variation and further investigation is required 
to resolve the cause of HI in those patients. 
The variations in MYO1A, USH2A and HSD17B4 may be explained away as the cause of HI in 
the patients due to abovementioned literature which indicates the implausibility of these 
variants as causative mutations in the patients. This is especially of note in HSD17B4 and 
USH2A, granting that the benign nature of the variation in USH2A is not considered, which are 
associated with syndromic HI. The patient population was specifically selected for non-
syndromic HI which means it is highly improbable that these genes are the causative mutations 
in the implicated patients. The variations in COL9A3, MYO3A, and MYO15A require further 
consideration. 
 
Chapter 4.2.1: Collagen type IX alpha 3 chain. 
COL9A3, encoded at position 20q13.33, is associated with Stickler Syndrome, which is mixed 
HI associated with myopia, cataracts, and retinal detachment, as well as facial abnormalities 
and precocious arthritis among other clinical manifestations (Robin et al., 2017). The syndrome 
is currently associated with six collagen genes, COL2A1, COL11A1, COL11A2, COL9A1, 
COL9A2, and COL9A3, though it is possible that other genes may also be responsible for the 
syndrome (Robin et al., 2017). The syndrome is inherited in an autosomal dominant pattern 
when the causative mutations are in the COL2A1, COL11A1 or COL11A2 genes. Conversely, 
the syndrome is inherited in a autosomal recessive pattern if the causative mutations are in the 
COL9A1, COL9A2 or COL9A3 genes (Robin et al., 2017). 
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COL9A3 forms one of the three alpha chains of Type IX Collagen and it is expressed in the 
inner ear and localised on the tectorial membrane (Abe et al., 2003). The HI associated with 
COL9A3 is due to COL9A3 and the Type IX being pertinent to the shape of the tectorial 
membrane and essential for the 3D structure of Type II collagen (Asamura et al., 2005), which 
is also associated with HI. 
The variation identified in COL9A3 has yet to be described in literature, the absence in clinical 
information accompanying the variant on rs145035835 on ClinVar and its rarity in both the 
Cameroonian patient and control population would have made it an attractive variant if it were 
validated by Sanger Sequencing. 
 
Chapter 4.2.2: Myosin 3A 
MYO3A, encoded at position 10p12.1, and was first reported to be associated with progressive, 
autosomal recessive, non-syndromic HI, previously identified as DFNB30 locus (MIM:60711 
and MIM:606808), by Walsh et al. (2002) in a multi-generational, Israeli family, originating 
from an endogamous population, indicated the Figure 4.3.1. The family was shown to carry 
three recessive MYO3A mutations that segregated with the family and resulted in HI in 
homozygotes and compound heterozygotes, where carriers were unaffected (Walsh et al., 
2002). Studies have indicated that MYO3A is responsible for the elongation of stereocilia by 
transporting espin 1 to the plus ends actin filaments in hair cells in cell culture (Salles et al., 
2009). Furthermore, that aberration in MYO3A, in mice models, results in fewer outer hair cells 
that indicate degeneration by the tenth month of life, which explains the progressive nature of 
the HI (Walsh et al., 2011). 
MYO3A has been associated with autosomal dominant, progressive HI in an African American 
family (Grati et al., 2016); the first study to do so. The study indicates that the mutation results 
in an aberration of the protein’s ATPase activity which the authors postulate may affect the 
motor-walking capabilities of the protein (Grati et al., 2016). This finding is also one of the 
first documented incidences where MYO3A was associated with a family of African descent 
and this variant is present in the heterozygous state in nine out of 121 064 alleles (Grati et al., 
2016), of which seven were in individuals of African ancestry and no homozygotes were 
observed. Though the MYO3A variant was not confirmed by Sanger Sequencing in the 
Cameroonian population, the study by Grati et al. (2016) may indicate that MYO3A may be an 





Chapter 4.2.3: Myosin 15A 
MYO15A, encoded at position 17p11.2, was initially associated with the DFNB3 HI locus in 
the individuals from the Bengkala and , neighbouring, Bali villages in Indonesia (Friedman et 
al., 1995; Winata et al., 1995), with the Bengkala families indicated in Figure 4.2.2.1. MYO15A 
was identified as the DFNB3 locus in 1998 through fine mapping (Liang et al., 1998; Probst et 
al., 1998; Wang et al., 1998). Probst et al. (1998) indicated that the HI was as a result of 
homozygous pathogenic mutations shortening the stereocilia bundles and disrupting the 
arrangement of the cell cytoskeleton in mice models. Further analysis identified that MYO15A 
Figure 4.2.2.1: Multi-
generational Israeli family 
segregating autosomal-recessive 
non-syndromic hearing 
impairment due to MYO3A 
mutations (adapted from Walsh 
et al., 2002). Proband family in 
which MYO3A was identified as 
the gene responsible for DFNB30. 
Family segregates three MYO3A 
mutations that result in hearing 
impairment in homozygotes and 
compound heterozygotes carrying 
two different mutations. Female 
members of the family are 
indicated by circles and male 
members of the family are 
indicated by squares. Affected 
individuals are indicated by filled 




is expressed as 2 isoforms in hair cells (Anderson et al., 2000; Belyantseva et al., 2005; Liang 
et al., 1999), whereby isoform 1 includes exon 2 of the MYO15A. gene which encodes a longer 
N-terminal domain and isoform 2 excludes exon 2 and the subsequent elongated N-terminal 
domain (Belyantseva et al., 2003; Liang et al., 1999), this is indicated in Figure 4.2.2.2. 
Isoform 2 is necessary for the early development of the stereocilia bundles ,including 
stereocilia elongation and the arrangement of the stereocilia bundles (Fang et al., 2015). 
Mutations in this isoform shortened stereocilia result in shortened stereocilia and slight 
perturbation of the stereocilia architecture being observed in mice models (Anderson et al., 
2000; Probst et al., 1998). The longer isoform of MYO15A is necessary for maintenance of the 
bundles (Belyantseva et al., 2005) and mutations that allow for the normal isoform 2, whilst 
disrupting isoform 1, result in normal stereocilia length and architecture at birth in mice models 
(Fang et al., 2015). The stereocilia, however, degenerate following 14 weeks after birth which 
coincides with when isoform 1 expression increases and isoform 2 expression decreases in 
mice models (Fang et al., 2015). 
The pathophysiology of these mutations differs in the sense that mutations that selectively 
target the elongated N-terminal domain present in isoform 1 will result in a progressive HI due 
to postnatal degeneration of the stereocilia, as in the case of a Pakistani individual (Nal et al., 
2007), on whom the pathogenic variation used in the isoform 2 mice models were based (Fang 
et al., 2015). Pathogenic variations that occur along the length of MYO15A, after the elongate 
N-terminal domain, will result in congenital HI due to the aberration in early development of 
the stereocilia bundles, as in the individuals from the Bengkala village (Friedman et al., 1995; 
Winata et al., 1995). 
Studies out of Morocco have implicated MYO15A in profound congenital HI in the population 




Figure 4.2.3.1: Pedigree of Bengkala families segregating MYO15A mutations responsible 
for DFNB3 non-syndromic hearing impairment (adapted from Winata et al., 1995). Pedigrees 
of six families segregating non-syndromic hearing impairment in the Bengkala village in 
Indonesia. The filled shapes indicate hearing impaired individuals, whereas unaffected 
individuals remain blank. Females are indicated by circles, males are indicated by squares and 




Chapter 4.2.4: Resolution of hearing impairment 
This study was capable of segregating putative causative mutations in 9 out of the 18 patients. 
If confirmed this could have been an improved diagnostic rate as compared to other studies 
utilising whole exome sequencing to study HI in African populations (Sloan-Heggen et al., 
2016); the study rather confirmed the low pick-up rate of causative mutations in known genes 
of HI. Furthermore, it increased the need to explore more familial cases in African populations 
so as to facilitate the discovery of novel genes and variants that are relevant to African HI, for 
use in clinical practice. Indeed, there is limited literature available regarding HI in African 
populations that doesn’t specifically focus on the connexin genes. Several studies have 
investigated the prevalence of the concern genes in African populations (Gasmelseed et al., 
2004; Javidnia et al., 2014; Kabahuma et al., 2011; Lasisi et al., 2014; Trotta et al., 2011), but 
there has been limited research into the other genetic causes of HI in African populations. 
 
Chapter 4.3: Candidate population specific variants 
Filtering variants from the WES data of entire Cameroonian population resulted in four variants 
being identified in four different genes that were population specific, as indicated in Table 7. 
These variants are not causative mutations of HI in the population and were discovered within 
the entire Cameroonian cohort, patients and controls, whereby the variants would only be 
  
  
Figure 4.2.3.2: Diagram of MYO15A indicating Isoform 1 and Isoform 2 (adapted 
from Fang et al., 2015). Isoform 1 and 2 of MYO15A are alternative splice variants of 
MYO15A which are expressed at different stages of stereocilia development. Isoform 2 is 
initially expressed and results in early formation of stereocilia bundles. Isoform 2 is 
expressed later in stereocilia development and is necessary for elongation and 
maintenance of the stereocilia bundles. 
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filtered if they were present in each individual in the merged data file. The variations also 
needed to be deemed pathogenic by 10 of the 15 filtering algorithms in order to be considered 
candidate variants, which makes these four protein changing variants filtered highly attractive 
variants of interest. 
 
Chapter 4.3.1: Forkhead Box D4 Like  
FOXD4L6, encoded at position 9p11.2, is one of six duplications of the FOXD4 gene (Jackson 
et al., 2010). The FOX gene family encodes transcription factors (Jackson et al., 2010), 
whereby the first FOX gene was discovered in Drosophila melanogaster as fkh (Weigel et al., 
1989). fkh was shown to be restricted in the nucleus (Weigel et al., 1989) and it contains an 
approximately 100 to 110 amino acid DNA binding domain conserved within members of this 
family (Fan et al., 2002; Jackson et al., 2010; Lai et al., 1991).The gene family has been shown 
to be implicated in embryonic development (Ruiz et al., 1993) and they have been shown to be 
oncogenes (Li and Vogt, 1993) and they have been implicated in various cancers (Katoh et al., 
2013; Zhang et al., 2014). Despite the suggested importance of the FOX genes, the functional 
roles of many of these genes is unknown (Jackson et al., 2010; Zhang et al., 2014) and this 
notion extends to FOXD4L6. 
The segregation of the FOXD4L6 variant with the Cameroonian population makes it of interest, 
as it may be associated with the HI phenotype in the population, though it does not actively 
cause HI in and of itself. The lack of literature/information regarding its exact function, 
however, renders the justification of the possible association rather complex as the possible 
action of FOXD4L6 is completely unknown. FOXD4L6 will need to be extensively studied 
within the population and its expression and possible function in the inner ear will need to be 
determined. The possibility does exist that it interacts with other HI associated genes, as it is a 
transcription factor, but to what extent would need to be determined. 
 
Chapter 4.3.2: Short chain dehydrogenase/reductase member 4 like 2 
DHRS4L2, encoded at position 14q11.2, as part of the DHRS4 gene cluster (Gabrielli and 
Tofanelli, 2012). The gene arose from duplication of DHRS4 and forms the gene cluster with 
DHRS4 and DHRS4L1 (Gabrielli and Tofanelli, 2012). DHRS4L2 has an alternative 
transcription start site in an exon prior to its exon 1  and the gene may be alternatively splice 
to produce alternative two transcripts (Zhang et al., 2009); denoted exon Ea in Figure 4.3.2.1a. 
The first alternative transcript of DHRS4L2 does not contain exons 1, 4, 5 and 6 and the second 
alternative transcript of DHRS4L2 is missing the above mentioned exons as well as exon 3 
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(Zhang et al., 2009), as indicated in Figure 4.3.2.1b. DHRS4L2 has been shown to be expressed 
only in neuroblastoma cells and that expression is limited to transcription of the DNA into 
RNA (Zhang et al., 2009), whereby the RNA product is stable and may be involved in gene 
expression regulation (Su et al., 2010), though this needs to be verified through molecular 
experiments. 
The absence of a known DHRS4L2 protein means that the function of the protein is unknown 
which makes its association with the Cameroonian population difficult to conceptualise. The 
possibility exists that DHRS4L2 is involved in regulating gene expression as indicated by Su 
et al. (2010) but further experimentation will be necessary to verify this. Alternatively, 
DHRS4L2 may possibly encode a protein that has yet to be identified similarly to DHRS4L1 
which was identified through a novel bioinformatics approach coupled with mass spectrometry 
analysis (Carapito et al., 2015). Regardless of the existence of a protein product for DHRS4L2, 
analysis of its involvement within the Cameroonian population may possibly determine 
whether it may regulate gene expression, though it will be necessary to first establish if it is 
expressed in the inner ear first. 
 
Chapter 4.3.3: Ribosomal Protein L3 Like 
The significance and worth, with regards to HI, of RPL3L, which is encoded at position 16p13, 
may be disputed. RPL3L, is a structural component of large ribosomal subunit, and it has been 
Figure 4.3.2.1:  DHRS4 gene cluster structure consisting of DHRS4 and DHRS4L2 (adapted from 
Zhang et al., 2009). Figure 3.5.2.1a indicates the structure of the DHRS4 gene cluster, including the 
position of the exon Ea which also possesses a transcription start site for DHRS4L2. Figure 5.3.2.1b 
indicates the alternatively spliced RNAs for DHRS4L2, which consist of exon Ea and exon exclude exons 
1, 4, 5, and 6 for the long transcript and exons 1, 3, 4, 5 and 6 for the short transcript. 
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previously shown to be expressed at high levels in the heart, skeletal muscle and at low 
expression in the pancreases, brain, placenta, lung liver and kidneys (Van Raay et al., 1996). 
The expression pattern is contrasted by Thorrez et al. (2008) and Gupta and Warner (2014) 
who indicate that RPL3L is only expressed in muscle tissue. Instead of RPL3L, it is RPL3 which 
is expressed in non-muscle tissue according to the 2008 study (Thorrez et al., 2008). This 
information results in a great deal of ambiguity regarding the plausibility of this gene playing 
any role in HI, including a modifier role. 
A further point of contention to be noted is that RPL3L was part of a gene-rich interval deleted 
in an individual with tuberous sclerosis and acrofacial dystosis, presenting with HI (Dauwerse 
et al., 2002). No follow-up study has been performed, to the best of our knowledge, to refine 
the region and determine the gene responsible for the phenotype in this individual, and as such, 
further ambiguity exists regarding the role of RPL3L in the disease status of the individual 
presented by Dauwerse et al. (2002)). This ambiguity extends to the role the RPL3L may play 
within the Cameroonian population and future work would need to address 1) the possibility 
that RPL3L is expressed in the inner ear instead of RPL3 and 2) the role that RPL3L, if any 
exists, plays in HI and how it functions to achieve the role. 
 
Chapter4.3.4: Vitronectin 
VTN, encoded at position 17q11.2, was initially sequenced by Jenne and Stanley (1985) and it 
is a secreted protein that exists and acts in the extracellular matrix where it is involved in cell 
attachment and spreading (Schvartz et al., 1999). The protein functions in the complement 
system where it interferes with complement-mediated cell lysis (Bhakdi and Roth, 1981; Kolb 
and Muller-Eberhard, 1975; Podack et al., 1977) and protects thrombin from inactivation by 
antithrombin III (Podack and Müller-Eberhard, 1979).  
VTN was been shown to be expressed in the inner ear by Aarnisalo et al. (2010), which renders 
it a more attractive candidate than RPL3L in having any role in HI within the Cameroonian 
population. The exact site, in the inner ear, where VTN is expressed was not indicated nor was 
the role of VTN in the inner ear elucidated in the study. Interestingly, VTN deposits have been 
shown to be associated with fibrosis and necrosis in a variety of diseases (Schvartz et al., 1999), 
though mice models, with null mutations in either one or both copies of VTN, have been shown 
to be healthy (Zheng et al., 1995). This may indicate that mutations in VTN in and of themselves 
may not result in disease, but they may affect the phenotype associated with the disease. The 
effect on the disease phenotype may be limited to the presence of VTN deposits and this would 
need to be further investigated to draw any meaningful conclusions. 
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Furthermore, taking this information into account, the presence of deleterious mutations in VTN 
in the Cameroonian population will need to be explored further. VTN may not necessarily be 
pathogenic, but it could possibly be a modifier of the HI phenotype observed within the 
Cameroonian population. If this be the case, the study of VTN with respect to HI may assist in 
understanding the variability sometimes observed within individuals who carry the same HI 
mutations. 
 
Chapter 4.3.5: Bias 
The population specific variants and the clinical variants discovered were due to mapping and 
comparison with the hg19 reference genome (Meyer et al., 2013) available from the UCSC 
Genome Browser. Though the variants were annotated and filtered according to various tools 
that predict pathogenicity, the possibility of false positives may not be ignored. The proportion 
of ethnic minorities whose genomes have contributed to developing the reference genome is 
not stated and no data is available on this percentage. There is, however, a persistent bias in 
genome wide association studies whereby the majority of studies are performed in European 
populations (Popejoy and Fullerton, 2016) and African populations are not well represented in 
exome databases (Lek et al., 2016; Manrai et al., 2016) and this may possibly extend to the 
genome assembly. This would result in polymorphisms been labelled as pathogenic simply due 
to their difference from the established normal. As such, increase in the African Exome 
proportion in datasets should improve inference of variants deleteriousness (Lek et al., 2016; 
Manrai et al., 2016); as well as subsequent functional analysis of the variants discovered is 
imperative to establish their pathogenicity. 
 
Chapter 4.4: Population structure and genetic differentiation 
Population structure analysis was performed through the use of two principle component 
analyses. Figure 4.3.1 indicates that both the patient and control population originate from one 
population confirming that the control population is sufficient to contrast any discoveries made 
within the patient population against. The figure indicates that the DRC population clusters 
with the Cameroonian population. This may simply be due to the small sample size used for 
the DRC population whereby only samples were used in the PCA from the DRC. A second 
PCA will need to be run with a greater sample population representation from the DRC in order 
to verify this hypothesis.  
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Figure 4.3.2 is the second PCA which compares the Cameroonian hearing impaired population 
to the unaffected control population. Neither population indicates any clustering and the 
samples are dispersed freely within the PCA indicating that no population stratification that 
may need to be corrected for. This PCA also verifies that the two sample populations originate 
from one population and that the control population is an adequate control for the downstream 
analysis. 
A novel approach analysed the genetic difference between hearing impaired population and 
control population. It aggregated the SNP frequencies in each gene and compared the aggregate 
between the populations. This approach allowed for the evaluation of possible difference 
between the populations which was summarised in Table 9. This data indicates a difference in 
aggregate frequencies between the hearing-impaired population and control population with 
regard to VTN and RPL3L; which both show unusual genetic differentiation. The novelty of 
this approach means there is no literature to compare to, but this approach adds evidence in the 
hypothesis that VTN and RPL3L are noteworthy genes regarding HI in the Cameroonian 
population. It thus supports the notion to further investigate the possible involvement of VTN 
and RPL3L within the HI context. Interesting, no data was produced for FOXD4L6 and 
DHRS4L2. 
 
Chapter 4.4: Protein-protein interactions, enrichment analysis and 
community network analysis 
Protein-protein interactions were analysed to determine what proteins VTN, RPL3L, 
FOXD4L6 and DHRS4L2 interact with as they have never been associated with HI before. 
VTN and RPL3L were shown to interact with 42 other proteins; with FOXD4L6 and DHRS4L2 
shown to interact with no other proteins; and the interactions were illustrated in Figure 4.4.1. 
The interactions show significant association with the osteoclast differentiation pathway. 
Aberrations in osteoclast differentiation has been shown to be associated with HI in mice (Akil 
et al., 2014; Kanzaki et al., 2006) and HI in osteogenesis imperfecta (Kuurila et al., 2002; 
Paterson et al., 2001; Pedersen, 1984; Pillion et al., 2014). 
The protein products of VTN, RPL3, DHRS4L2 and FOXD4L2 were combined to produce a 
network plot. This network plot indicated VTN and ATPB2 as the hub proteins of one of the 8 
subnetworks generated. This involvement of VTN as hub protein supports its notion as having 
a contribution in HI within our population. ATPB2, as a second hub protein in the subnetwork, 
may rescue the subnetwork should VTN possess deleterious variations and this may explain 
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why mice with null mutations in VTN are healthy (Zheng et al., 1995). This will need to be 
explored further as a similar study by Lebeko et al. (2017) indicate that the hub protein of this 
subnetwork was DIAPH1, which is shown in this study to be a subsidiary protein. The 
difference in designated hub protein may be due to the genes used whereby this study compared 
159 genes whereas Lebeko et al. (2017) utilised 116 genes. 
This study and Lebeko et al. (2017), do indicate differences in the hub proteins identified; but 
a simplistic conclusion could be that all the hub proteins identified are of importance in HI and 
should be studied further in order to elucidate how they fit into the HI network. This study will 
be greatly assisted if further genes associated with HI are discovered and incorporated into the 
network such that a fuller picture of the HI network is established. 
The absence of DHRS4L2 and FOXD4L6 protein products, in Figure 4.4.1, may be due to the 
non-existence of the protein in the case of the former only or due to there being no annotation 
that indicates which proteins these particular proteins interact with. Studies will need to be 
performed which may allow for the exclusion of both genes as associated with HI, even in a 
modifier role, in the population, but the proposed gene expression regulatory role of the RNA 
products of DHRS4L2 and the transcription factor role of FOXD4L6 make both genes and the 
products interesting subjects for future studies. 
 
Chapter 4.6: Validation 
Cycle sequencing indicated the absence of the MYO3A and the MYO15A variations in all the 
patients purported to carry the variation. This absence of the variation could simply be that 
variations are absent in all the three MYO3A patients and in all the four MYO15A patients, but 
this seems highly unlikely. The possibility exists that the overall negative results may be due 
to errors in the sequencing; which may have arisen due to incorrect primers being utilised and 
would be concordant with results observed by Beck et al., (2016). The discrepancy in the next 
generation sequencing results vs the Sanger Sequencing  results was resolved for 17 of the 19 
SNPs (Beck et al., 2016). 
A valid approach to assess the discrepancy between Sanger Sequencing and the variant call by 
next generation sequencing would be to perform restriction fragment length polymorphisms 
for the rs140301218, in MYO3A, and rs138861831, in MYO15A. This approach is, however, 
not viable due to the absence of restriction sites surrounding the variants as indicated by 
Webcutter 2.0 (http://rna.lundberg.gu.se/cutter2/). 
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A more viable approach was to view the BAM files of the patients using the Integrative 
Genomics Viewer, or IGV (Robinson et al., 2011; Thorvaldsdóttir et al., 2013). This approach 
allows the researcher to visualise each variant call and the associated read depth for the variant. 
As such, viewing the BAM files using IGV supports the results from Sanger Sequencing for 
MYO3A, indicating that the variants observed in Bioinformatics analysis were incorrect and the 
patients with the purported to carry the causative mutations. This approach further indicated 
the absence of the variant in COL9A3 in the patients that were purported to carry the variant 
and as such, the resolution rate regarding putative causative mutations in this population is 0%. 
The approach furthermore resolved the discrepancy in the Sanger Sequencing results for patient 
CAM103 by providing supporting evidence for the sequencing result indicated in 4.8.3B. 
 
Chapter 4.7: Evolutionary adaptation of human hearing 
Analysis of the fraction of ancestral alleles in the population, indicated in Figure 4.7.1, yielded 
expected results with regards to the proportion of ancestral and derived alleles in the patient 
and control populations. The hearing-impaired patient population presented with a higher 
proportion of derived alleles at low population frequencies (the 0.00 to 0.10 MAF bins). The 
proportion of the derived alleles decreased with increasing population frequencies, such that 
there was a higher proportion of ancestral alleles at population frequencies indicative of 
common alleles. This result was similar to the results of a study by Gorlova et al. (2012), which 
found a higher proportion of derived alleles at low population frequencies and this proportion 
(of derived alleles) decreases with an increase in the population frequencies, and they further 
showed that derived alleles are associated with disease risk (Gorlova et al., 2012). 
Analysis further contrasted the proportion of ancestral alleles in the Cameroonian Population 
and a Population from the Democratic Republic of Congo, indicated in Figure 4.7.2. Analysis 
showed variations in the two populations with regards to the proportion of ancestral alleles in 
various HI associated genes in the two populations. This may indicate that the subset of genes 
responsible for HI within one population cannot be juxtaposed on the other population and that 
independent research into the genetic causes of HI must be done within each population. This 
analysis should, however, be taken with a grain of salt due to the small sample size of the DRC 
population, which may explain the large spikes observed in the graph. 
A point of interest is that the proportion of derived alleles in GJB2 indicates that it may be of 
importance to HI within both the Cameroonian population and the Democratic Republic of 
Congo population and, maybe, possibly in a greater African context, as indicated in Figure 
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4.7.2. This contrasts published literature that has shown that GJB2 mutations are not prevalent 
within studied African populations (Bosch et al., 2014b; Gasmelseed et al., 2004; Javidnia et 
al., 2014; Kabahuma et al., 2011; Trotta et al., 2011), excepting in the Ghanaian (Hamelmann 
et al., 2001) and Moroccan (Gazzaz et al., 2005) populations, and the probable cause of this 
(the high proportion of derived alleles) may be due to GJB2 being a hypervariable gene. 
The novelty of this analysis within the African context and within African HI means there is 
very little literature to compare these findings to; despite this, the results from this analysis may 
be compared to the candidate variants discovered whereby COL9A3 was indicated to have a 
low proportion of ancestral alleles, and therefore a high proportion of derived alleles, in Figure 
4.7.2. This may possibly affirm its association as a putative causative mutation in HI in the 
individuals that carry this variation. A similar statement cannot necessarily be made about 
USH2A, which also indicates a low proportion of ancestral alleles, and thus a high proportion 
of derived alleles, simply because USH2A is solely associated with syndromic HI and none of 
the individuals who harboured the USH2A variations segregated syndromic HI. 
The result, in Figure 4.7.2, may also indicate genes of interest in Cameroonian population. The 
worth of this information will need to be evaluated by determining the minor allele frequencies 
where these variations occur and establishing whether the gene, similar to GJB2, is 
hypervariable or not. 
 
Chapter 4.8: Limitations of study 
The limitations of this study were the small sample size for the hearing-impaired population 
whereby the whole exome sequences from 18 individuals were analysed. This means that 
though cumulatively, if confirmed, the variations in COL9A3, MYO3A and MYO15A could 
have been putative causes of HI in 50% of the studied hearing-impaired population, the sample 
size was too small for the results to have any statistical power. This could have been remedied 
by screening the variations in a greater cohort of Cameroonian hearing-impaired patients, 
which would aid in establishing the significance of the variations discovered. 
A further limitation was that no segregation analysis was performed. This would have indicated 
if the variations discovered segregated with the families and would have ameliorated the lack 
of statistical power of the study. This could have been remedied by including the parents and 
of affected individuals and performing trio-studies, which would indicate the segregation 
pattern of the variations. 
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A final limitation of this study, which was beyond the scope of the study, was that no functional 
studies or protein modelling were performed in order to validate the pathogenicity of the 
variations discovered. The possible manner by which these variations cause HI would need to 
be studied through molecular analysis in order to conclude that the variations are indeed the 
causative mutations within the those who carry the variations in homozygosity. 
 
Chapter 4.9: Practical implications of the study 
The results support published literature indicating the low-resolution rate of the causative genes 
resulting in HI in African populations. The results further indicate that novel strategies may be 
necessary to discover causative variants resulting in HI in African populations, specifically the 
studies of multiple families segregating HI, from various settings and African populations, to 
discovery novel HI genes and novel variants in Known genes, that will be useful in clinical 
practice. 
 
Chapter 4.10: Perspectives and research recommendations 
Future work should focus on targeting familial cases of HI in multiple African populations in 
order to determine the prevalent genes associated with HI within African populations; as by 
determining these genes, it may be possible to create a diagnostic panel that may be used in the 
clinical settings to determine the cause of HI in patients with readily available results. This 
must however be augmented with whole genome sequencing and transcriptomic analysis; as 
the causative mutations may not necessarily be resulting in an aberration in the exonic or 
protein sequences, but in the expression of the genes. The errors that result in HI may be due 
to gene silencing which should be further explored. 
A second avenue of future work should also consider mutations that affect the genomic 
architecture that may result in HI. This should include copy number variations which has not 
necessarily been explored in African populations. 
Finally, a larger patient population is needed for further studies. The increased population size 
may result in better resolution of causative mutations resulting in HI in the population as well 
as lending statistical power to any results obtained. The increased population size may be 
recruited by collaborating with other researchers on the African continent in order to recruit 




Chapter 5: Conclusions and future directions 
The study aimed to determine known genes that may be prevalently associated with HI in Sub-
Saharan, and specifically Cameroonian, patients. This study demonstrates the low pick up rate 
of putative pathogenic variant in known genes in this group of patients.  The study also showed 
the efficacy novel approaches, in the bioinformatics analysis of whole exome sequencing data, 
in annotating genes variants according to their putative protein-protein interactions and 
network involvement in HI. This provides a novel insight into possible functions that the genes 
may adapt with regard to HI. The value of bioinformatics research is demonstrated in its use in 
indicating proteins of note which may have indirect effects on HI in the form of the hub proteins 
and the protein products of genes indicating unusual genetic difference between the hearing 
impaired and control populations. The proteins may not directly result in HI but perturbations 
within them may have downstream effects on the observed phenotype and this needs to be 
taken into account. Advancement of bioinformatics tools and methods allow for the in-silico 
prediction of protein interactions and incorporation of novel proteins into a protein product, 
but this must be substantiated with molecular analysis. The bioinformatics analysis provides 
an invaluable insight into the direction the molecular research ought to follow, but these are 
still predictions. That being said, the advancement of bioinformatics tools and the simultaneous 
incorporation of several tools in analysis is instrumental in generating new knowledge, 
especially in a heterogenous field such as genetic HI. 
The study, further, indicated that whole exome sequencing results should be viewed cautiously; 
perhaps more so when studying African exomes/genomes, as some putative causative variants 
identified in whole exome sequencing will not confirmed by other techniques such as Sanger 
Sequencing.  Whole exome sequencing resulting should be validated prior in order to ensure 
that the filtered variants are present in the patients. Furthermore, logical annotation of all 
candidate variants should be done whilst taking into account published literature regarding the 
involvement of the gene products in disease. This may however be complicated if there is a 
dearth in published literature regarding specific genes and/or their protein products. 
Lastly the study has confirmed the diagnostic limitation of using WES for known HI genes 
among this group of Africans, and therefore emphasizes the urgent need to study large numbers 
of African families with HI in order to determine the relevant novel genes and variants that will 
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Appendix 1: DNA extraction methods 
DNA Extraction using the Gentra Puregene Kit (QIAGEN Sample and Assay Technologies, 
2014) 
• Add 9ml of RBC lysis buffer to 4ml of whole blood and mix by inverting 10 times 
• Incubate for 5 minutes at room temperature (15°C to 25°C) and invert at least once during 
the incubation 
• Centrifuge the sample for 2 minutes at 2 000gto pellet out the white blood cells 
• Discard the supernatant carefully, leaving the pellet and 200µl residual liquid 
• Vortex the sample vigorously until the pellet is completely resuspended 
• Add 3ml cell lysis solution and pipette mix prior to vortexing for 10 seconds 
• Add 15µl RNase to the solution and mix by inverting 25 times prior to incubating at 37°C 
for 15 minutes 
• Add 1 ml protein precipitation solution and vortex, at high speed, for 20 seconds 
• Centrifuge the solution for 5 minutes at 2 000g 
• Add 3ml of isopropanol into a clean 15ml tube and carefully add the supernatant from the 
previous step by pouring 
• Mix by inverting 50 times until the DNA is visible as threads or a clump 
• Centrifuge for 3 minutes at 2 000g such that the DNA is visible as a clear white pellet 
• Discard the pellet carefully and drain the tube by inverting on a clean piece of absorbent 
paper; taking care not disturb the pellet 
• Add 3ml of 70% ethanol and invert several times to wash the DNA pellet 
• Centrifuge at 2 000g for 1 minute 
• Discard the pellet carefully and drain the tube by inverting on a clean piece of absorbent 
paper; taking care not disturb the pellet; and air dry for 5 to 10 minutes 
• Add 300µl of DNA hydration solution and vortex at medium speeds for 5 seconds to mix 
• Incubate at 65°C for 1 hour to dissolve the DNA 
• Incubate overnight with gentle shaking. 






DNA extraction using modified salting out method 
• If fresh blood has a volume of 3ml or less, transfer the blood into a 15ml conical tube, 
else make a buffy for blood greater than 3ml and transfer 3ml of the buffer into a 15ml 
conical tube 
• Add 9ml of filter sterilised red blood cell lysis buffer and incubate for 30 minutes at room 
temperature following mixing 
• Vortex the solutions and centrifuge for 10 minutes at 2 000rpm 
• Decant the supernatant and add 1ml of fresh red blood cell lysis buffer and vortex to mix 
the solution until the pellet is resuspended. 
o Repeat this step and the previous centrifugation step to ensure that the pellet is 
clean 
• Add 3ml of filter sterilised cell lysis buffer and vortex to mix 
• Add 12.5µl of 20mg/ml Proteinase K and 100µl of 20% SDS to each tube and vortex to 
mix 
• Incubate the samples, in a water bath, at 37°C for 1 to 3 days 
o There should be no pellet and the liquid should be clear following this step 
• Add 1ml of 6M NaCl and vortex vigorously to mix 
• Centrifuge at 2 000rpm for 20 minutes and transfer 5ml of the supernatant into a clean 
15ml conical tube 
• Add 10ml of 100% ethanol and mix gently but inverting 50X 
• Centrifuge for 10 minutes at 2 000rpm 
• Decant the supernatant and add 2ml of ice cold 70% ethanol to the solution 
• Centrifuge or 10 minutes at 2 000rpm and carefully remove the supernatant without 
disturbing the DNA pellet 
• Air dry at room temperature the pellet for 2 hours, or until dry 
• Resuspend the pellet in 150µl DNA rehydration solution and leave at room temperature 
for one week to ensure complete resuspension. 
• Transfer the DNA into storage tubes 
 
Buffy coat preparation 
• Centrifuge whole blood sample at 2 500rpm for 20 minutes 






Appendix 2: Reagents and buffers 
TE Buffer 
5ml of 1M Tris-HCl (pH 8) 
1ml of 0.5M EDTA 
500ML distilled H2O 
Autoclave 
 
Polymerase Chain Reaction 
Sabax water for injections 
Adcock In 
Lot number: S8513 
 
GoTaq® G@ DNA Polymerase 
Promega 




Lot number: DCTP3400 
 
Primer 
Whitehead Scientific  
 
Gel Electrophoresis 
Seakem® LE Agarose 
Lonza 
Lot number: 0000 5718 11 
 
GeneRuler 1kb DNA Ladder 
Thermo Scientific 





SYBR ® Safe DNA gel stain 
Invitrogen 
Lot number:1906 577 
 
10X TBE (1l) 
7.5g EDTA Di-Sodium Salt  
Nexgen Chemical 
Batch number: NEX-90030 
 
55g Boric acid 
 
108g Tris   
Melford Biolaboratories  
Batch number: 2641 
 
Procedure 
• Components measured out in 1l Erlenmeyer flask 
• Add 750ml distilled H2O 
• Heat content whilst stirring until the powder is completely dissolved 
• Decant into 2l measuring cylinder and fill up to 1l mark with distilled H2O 
• Pour into a 1l labelled bottle. 
 
PCR Clean-up 
FastAP Thermosenstive Alkaline Phosphatase 
Thermo Scientific 




Lot number: 0024 9850 
 
Direct Cycle Sanger Sequencing 





Lot number:1507 380 
 
Appendix 3: Equipment and machines 
NanoDrop® ND-1000 Spectrophotometer 
Serial number 4206 
ND-1000 Software v3.8.1 
 
SimpliAmo Thermal Cycler 
Applied Biosysterms 
 
PS500XT DC Power Supply 
Hoefer Scientific Instruments 
 








UVIpro Version 12.3 for Windows 
 
3130xl Genetic Analyzer 
ABI Prism 
Applied Biosystems | Hitachi 
FoundationData Collection Version 3.1.1 
Sequencing Analysis v5.4 
 










Appendix 4: PCR and clean-up constituents and protocols 
MYO3A and MYO15A PCR Constituents 
 
PCR Protocol 
Step Temperature (°C) Time 
Initial Denaturation 95 3 Minutes 
Denaturation 94 30 Seconds 
Primer Annealing 61 40 Seconds 
Elongation 72 1 Minute 
Final Elongation 72 10 minutes 
The denaturation, primer annealing and elongation steps are performed for 35 cycles for 
MYO3A and for 45 cycles for MYO15A 
 
PCR Clean-up 
Reagent n=1 (µl) 
PCR Product 17.8 
FastAP 2.0 
Exo1 0.2 
Total volume 20 
 
Reagent Stock Required n=1 (µl) 
dH2O - - 16.9 
Taq Buffer 5X 1X 5 
dNTPs 5mM 200µM 1 
Forward Primer 20µM 0.04µM 0.5 
Reverse Primer 20µM 0.04µM 0.5 
Taq 5U/µL 0.02µM 0.1 
DNA - 100ng/µl 1 
Total volume - - 25 
vii 
PCR Clean-up Protocol 
Temperature (°C) Time 
Incubation 37 1 hour 
Deactivation 75 15 minutes 
Appendix 5: Sequencing and clean-up constituents and protocols 
Sodium Acetate Precipitation 
Cycle sequencing 
Reagent n=1 (µl) 
dH2O 4.5 
Dilution Buffer 2 
Terminator Mix 1 
Primer 0.5 
PCR Product 2 
Total Volume 10 
Protocol 
Step Temperature (°C) Time 
Initial Denaturation 96 5 minutes 
Denaturation 96 30 seconds 
Primer Annealing 50 15 seconds 
Elongation 60 4minutes 
Cycle sequencing proceeds with 30 cycles of the denaturation primer annealing and elongation 
steps. 
Ethanol and Sodium Acetate Precipitation 
Reagent n=1 (µl) 
100% Ethanol 50 
Sodium acetate 2 





Samples are incubated at -20°C 
for 8 hours
Centrifuge samples for 10 
minutes at 10 000g
Remove supernatant and 
resuspend pellet in 50µl 70% 
ethanol
Vortex samples to mix 
Centrifuge samples for 10 
minutes at 10 000g
Air dry samples for one hour or 
until completely dry
Resuspend samples in 10µl 
HiDi Formamide
Load samples onto the 31030xl 







Reagent n=1 (µl) 
dH2O 8.5 
Dilution Buffer 4 
Terminator Mix 2 
Primer 0.5 
PCR Product 5 
Total Volume 20 
 
Protocol 
Step Temperature (°C) Time 
Initial Denaturation 96 5 Minutes 
Denaturation 96 30 Seconds 
Primer Annealing 50 15 Seconds 
Elongation 60 4 Minutes 




Ethanol and EDTA Precipitation 
20µl sequencing product or 10 µl sequencing product diluted with 10µl Sabax water 
Add 5µl 0.125 EDTA to 96 well plate
Transfer 20µl rxn to 96 well plate and mix 
well
Add 60µl 100% ETOH and Seal plate
Vortex for 2 to 3 seconds
Transfer the plate to an ice block and the -
20°Cfor 15 minutes
Seal the plate and centrifuge at1870g for 45 
minutes (at room temperature)
Remove the seal and invert plate on paper 
towel
Centrifuge at180g for 1 minute (at room 
temperature)
Add 60µl 70% ETOH (diluted with nuclease 
free H2O
Seal the plate and centrifuge at 1870g for 15 
minutes (at room temperature)
Remove the seal and invert on paper towel
Centrifuge at 180g for 1 minute ((at room 
temperature)
Air Dry for 10 minutes in a dark drawer
Add 10µl HiDi Formamide and Sequence on 




Appendix 6: 179 hearing impairment associated genes investigated 
Number Gene name Number Gene name3 Number Gene name Number Gene name 
1 ACTG1 51 EPS8 101 MT-TK 151 SLC26A5 
2 ADCY1 52 EPS8L2 102 MT-TL1 152 SLITRK6 
3 ADGRV1 53 ESPN 103 MT-TL2 153 SMC1A 
4 ADGRV1  54 ESRRB 104 MT-TS1 154 SMPX 
5 AIFM1 55 EYA1 105 MYH14 155 SNAI2 
6 ALMS1 56 EYA4 106 MYH9 156 SOX10 
7 APC 57 F2 107 MYO15A 157 SPRY4 
8 ATP1A3 58 FAM65B 108 MYO3A 158 STRC 
9 ATP2B2 59 FBN1 109 MYO6 159 SYNE4 
10 ATP6V1B1 60 FGF3 110 MYO7A 160 TBC1D24 
11 BDP1 61 FGFR1 111 NARS2 161 TBX1 
12 BSND 62 FGFR2 112 NDUFA1 162 TCOF1 
13 C10orf2 63 FGFR3 113 NLRP3 163 TECTA 
14 CABP2 64 FOXI1 114 OPA1 164 TECTB 
15 CACNA1D 65 GATA3 115 OSBPL2 165 TIMM8A 
16 CCDC50 66 GBE1 116 OTOA 166 TJP2 
17 CD164 67 Gene(s) 117 OTOF 167 TMC1 
18 CDC14A 68 GIPC3 118 OTOG 168 TMEM132E 
19 CDH23 69 GJB2 119 OTOGL 169 TMIE 
20 CDH23 70 GJB3 120 P2RX2 170 TMPRSS3 
21 CDK5RAP2 71 GJB6 121 PAFAH1B1 171 TNC 
22 CEACAM16 72 GPSM2 122 PAX3 172 TPRN 
23 CIB2 73 GRHL2 123 PCDH15 173 TRIOBP 
24 CISD2 74 GRXCR1 124 PDZD7 174 TSPEAR 
12 
25 CLDN14 75 GRXCR2 125 PEX1 175 USH1C 
26 CLIC5 76 HARS2 126 PEX6 176 USH1G 
27 CLPP 77 HGF 127 PJVK 177 USH2A 
28 CLRN1 78 HOMER2 128 PMP22 178 WFS1 
29 COCH 79 HSD17B4 129 PNPT1 179 WHRN 
30 COCH 80 ILDR1 130 POLG 
31 COL11A1 81 KARS 131 POLR1C 
32 COL11A2 82 KCNE1 132 POLR1D 
33 COL2A1 83 KCNJ10 133 POU3F4 
34 COL4A3 84 KCNQ1 134 POU4F3 
35 COL4A4 85 KCNQ4 135 PRF1 
36 COL4A5 86 KITLG 136 PRPS1 
37 COL4A6 87 LARS2 137 PRRT2 
38 COL9A1 88 LHFPL5 138 PTPRQ 
39 COL9A2 89 LOXHD1 139 PTRH2 
40 CRYM 90 LOXL3 140 RAI1 
41 DCDC2 91 LRTOMT 141 RDX 
42 DFNA5 92 MARVELD2 142 ROR1 
43 DIABLO 93 MBTPS2 143 S1PR2 
44 DIAPH1 94 MCM2 144 SERPINB6 
45 DIAPH3 95 MET 145 SIX1 
46 DSPP 96 MIR96 146 SIX5 
47 DYNC1H1 97 MITF 147 SLC17A8 
48 EDN3 98 MSRB3 148 SLC22A4 
49 EDNRB 99 MT-CO1 149 SLC26A4 
50 ELMOD3 100 MT-RNR1 150 SLC26A4 
